US20090176799A1 - Phosphodiesterase 4 inhibitors - Google Patents

Phosphodiesterase 4 inhibitors Download PDF

Info

Publication number
US20090176799A1
US20090176799A1 US12/325,433 US32543308A US2009176799A1 US 20090176799 A1 US20090176799 A1 US 20090176799A1 US 32543308 A US32543308 A US 32543308A US 2009176799 A1 US2009176799 A1 US 2009176799A1
Authority
US
United States
Prior art keywords
pyrrolidone
methoxyphenyl
cyclopentyloxy
alkyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/325,433
Inventor
Liu Ruiping
Mike De Vivo
Hans-Jurgen Ernst Hess
Allen Hopper
Erik Kreuster
Ashok Tehim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US12/325,433 priority Critical patent/US20090176799A1/en
Publication of US20090176799A1 publication Critical patent/US20090176799A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates generally to the field of phosphodiesterase 4 (PDE4) enzyme inhibition. More specifically this invention relates to selective PDE4 inhibition by novel compounds, e.g., 4-(substituted-phenyl)-2-pyrrolidinone compounds, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
  • novel compounds e.g., 4-(substituted-phenyl)-2-pyrrolidinone compounds
  • the cyclic nucleotide specific phosphodiesterases represent a family of enzymes that catalyze the hydrolysis of various cyclic nucleoside monophosphates (including cAMP and cGMP). These cyclic nucleotides act as second messengers within cells, and as messengers, carry impulses from cell surface receptors having bound various hormones and neurotransmitters. PDEs act to regulate the level of cyclic nucleotides within cells and maintain cyclic nucleotide homeostasis by degrading such cyclic mononucleotides resulting in termination of their messenger role.
  • PDEs cyclic nucleotide specific phosphodiesterases
  • PDE enzymes can be grouped into eleven families according to their specificity toward hydrolysis of cAMP or cGMP, their sensitivity to regulation by calcium, calmodulin or cGMP, and their selective inhibition by various compounds.
  • PDE 1 is stimulated by Ca 2+ /calmodulin.
  • PDE 2 is cGMP-dependent, and is found in the heart and adrenals.
  • PDE 3 is cGMP-inhibited, and inhibition of this enzyme creates positive inotropic activity.
  • PDE 4 is cAMP specific, and its inhibition causes airway relaxation, anti-inflammatory and antidepressant activity.
  • PDE 5 appears to be important in regulating cGMP content in vascular smooth muscle, and therefore PDE 5 inhibitors may have cardiovascular activity. Since the PDEs possess distinct biochemical properties, it is likely that they are subject to a variety of different forms of regulation.
  • PDE4 is distinguished by various kinetic properties including low Michaelis constant for cAMP and sensitivity to certain drugs.
  • the PDE4 enzyme family consists of four genes, which produce 4 isoforms of the PDE4 enzyme designated PDE4A, PDE4B, PDE4C, and PDE4D [See; Wang et al., Expression, Purification, and Characterization of human cAMP-Specific Phosphodiesterase (PDE4) Subtypes A, B, C, and D, Biochem. Biophys. Res. Comm., 234, 320-324 (1997)].
  • PDE4A PDE4A
  • PDE4B PDE4C
  • PDE4D PDE4D
  • PDE4 isoenzymes are localized in the cytosol of cells and are unassociated with any known membranous structures. PDE4 isoenzymes specifically inactivate cAMP by catalyzing its hydrolysis to adenosine 5′-monophosphate (AMP). Regulation of cAMP activity is important in many biological processes, including inflammation and memory, Inhibitors of PDE4 isoenzymes such as rolipram, piclamilast, CDP-840 and airflo are powerful anti-inflammatory agents and therefore may be useful in treating diseases where inflammation is problematic such as asthma or arthritis. Further, rolipram improves the cognitive performance of rats and mice in learning paradigms.
  • cAMP and cGMP are second messengers that mediate cellular responses to many different hormones and neurotransmitters.
  • PDE inhibition may result from PDE inhibition and the resulting increase in intracellular cAMP or cGMP in key cells, such as those located in the nervous system and elsewhere in the body.
  • Rolipram previously in development as an anti-depressant, selectively inhibits the PDE4 enzyme and has become a standard agent in the classification of PDE enzyme subtypes.
  • Early work in the PDE4 field focused on depression and inflammation, and has subsequently been extended to include indications such as dementia, [see “The PDE IV Family Of Calcium-Phosphodiesterases Enzymes,” John A. Lowe, III, et al., Drugs of the Future 1992, 17(9):799-807 for a general review]. Further clinical developments of rolipram and other first-generation PDE4 inhibitors were terminated due to the side effect profile of these compounds.
  • the primary side effect in primates is emesis, while the primary side effects in rodents are testicular degradation, weakening of vascular smooth muscle, psychotrophic effects, increased gastric acid secretion and stomach erosion. In humans, the primary side effect is nausea and emesis.
  • the present invention relates to novel compounds that inhibit, preferably selectively, PDE4 enzymes, and especially have improved side effect profiles, e.g., are relatively non-emetic (e.g., as compared to the previously discussed prior art compounds).
  • the present invention relates to novel rolipram analogs.
  • the compounds of this invention at the same time facilitate entry into cells, especially cells of the nervous system.
  • the present invention provides methods for synthesizing compounds with such activity and selectivity as well as methods of (and corresponding pharmaceutical compositions for) treating a patient, e.g., mammals, including humans, in need of PDE inhibition, especially PDE4 inhibition, for a disease state that involves elevated intracellular PDE 4 levels or decreased cAMP levels, e.g., involving neurological syndromes, especially those states associated with memory impairment, most especially long term memory impairment, as where such memory impairment is due at least in part to catabolism of intracellular cAMP levels by PDE 4 enzymes, or where such an impaired condition can be improved by increasing cAMP levels.
  • the compounds of the inventions improve such diseases by inhibiting PDE4 enzymes at doses that do not induce emesis or other side effects.
  • the present invention includes compounds of Formula I:
  • a method of treating a patient e.g., a mammal such as a human
  • a disease state e.g., memory impairment
  • administering comprising administering to the patient a compound according to formula I′:
  • the compounds of the present invention are effective in inhibiting, or modulating the activity of PDE4 in animals, e.g., mammals, especially humans. These compounds exhibit neurological activity, especially where such activity affects cognition, including long term memory. These compounds will also be effective in treating diseases where decreased cAMP levels are involved. This includes but is not limited to inflammatory diseases. These compounds may also function as antidepressants, or be useful in treating cognitive and negative symptoms of schizophrenia.
  • Halogen herein refers to F, Cl, Br, and I. Preferred halogens are F and Cl.
  • Alkyl means a straight-chain or branched-chain aliphatic hydrocarbon radical.
  • suitable alkyl groups have preferably 1 to 8 carbon atoms, especially 1 to 4 carbon atoms.
  • suitable alkyl groups have preferably 1 to 4 carbon atoms.
  • suitable alkyl groups have preferably 1 to 12 carbon atoms, especially 1 to 8 carbon atoms, in particular 1 to 4 carbon atoms.
  • Suitable alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, and dodecyl.
  • alkyl groups include 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, ethylmethylpropyl, trimethylpropyl, methylhexyl, dimethylpentyl, ethylpentyl, ethylmethylbutyl, dimethylbutyl, and the like.
  • alkyl radicals can optionally have one or more —CH 2 CH 2 — groups replaced in each case by —CH ⁇ CH— or —CC— groups.
  • Suitable alkenyl or alkynyl groups are 1-propenyl, 2-propenyl, 1-propynyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-butynyl, 1,3-butadienyl and 3-methyl-2-butenyl.
  • the substituted alkyl groups for R 1 , R 3 , R 4 and R 5 are alkyl groups as described above which are substituted in one or more positions by halogens and/or oxo.
  • Halogens are preferred substituents, especially F and Cl.
  • the substituted alkyl groups have 1 to 4 carbon atoms and are substituted one or more times by halogen, especially F and Cl, e.g., C 1 -C 4 alkyl substituted by up to five F atoms.
  • alkyl refers to a divalent alkylene group having in general up to about 13 carbon atoms.
  • the “alkyl” portion has preferably 2 to 10 carbon atoms.
  • the “alkyl” portion has preferably 1 to 10.
  • the heterocyclic-alkyl groups the “alkyl” portion preferably has 1 to 12 carbon atoms.
  • the alkoxyalkyl groups the “alkyl” portion preferably has 2 to 7 carbon atoms.
  • the “alkyl” portion preferably has 1 to 13 carbon atoms.
  • alkyl is a substituent (e.g., alkyl substituents on aryl and heterocyclic groups) or is part of a substituent (e.g., in the alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, alkylthio, alkylsulphinyl, and alkylsulphonyl substituents for aryl)
  • the alkyl portion preferably has 1 to 12 carbon atoms, especially 1 to 8 carbon atoms, in particular 1 to 4 carbon atoms.
  • Alkoxy means alkyl-O— groups in which the alkyl portion has 1 to 8 carbon atoms. Suitable alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, isobutoxy, sec-butoxy, pentoxy, hexoxy, heptoxy, octoxy, and trifluoromethoxy. Preferred alkoxy groups are methoxy and ethoxy.
  • the alkoxyalkyl group for R 3 preferably has 3 to 8 carbon atoms, e.g., methoxyethyl.
  • alkoxycarbonyl means an alkyl-O—CO— group in which the alkyl portion has 1 to 8 carbon atoms.
  • Alkenyl refers to straight-chain or branched-chain aliphatic radicals containing 2 to 12 carbon atoms in which one or more —CH 2 —CH 2 — structures is replaced by —CH ⁇ CH—.
  • Suitable alkenyl groups are ethenyl, 1-propenyl, 2-methylethenyl, 1-butene, 2-butene, 1-pentenyl, and 2-pentenyl.
  • alkenyl refers to an alkyenylene group having preferably 2 to 5 carbon atoms.
  • Cycloalkyl means a monocyclic, bicyclic or tricyclic saturated hydrocarbon radical having 3 to 8 carbon atoms, preferably 4 to 6 carbon atoms, especially 5 carbon atoms.
  • Suitable cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and norbornyl.
  • Suitable cycloalkyl groups include spiropentyl, bicyclo[2.1.0]pentyl, bicyclo[3.1.0]hexyl, spiro[2.4]heptyl, spiro[2.5]octyl, bicyclo[5.1.0]octyl, spiro[2.6]nonyl, bicyclo[2.2.0]hexyl, spiro[3.3]heptyl, and bicyclo[4.2.0]octyl.
  • the preferred cycloalkyl group is cyclopentyl.
  • the cycloalkyl group can be substituted by halogens, oxo and/or alkyl. Halogens and/or alkyl groups are preferred substituents.
  • Cycloalkylalkyl refers to a cycloalkyl-alkyl-radical in which the cycloalkyl and alkyl portions are in accordance with the previous descriptions. Suitable examples include cyclopentylethyl and cyclopropylmethyl.
  • Aryl as a group or substituent per se or as part of a group or substituent, refers to an aromatic carbocyclic radical containing 6 to 14 carbon atoms, preferably 6 to 12 carbon atoms, especially 6 to 10 carbon atoms.
  • Suitable aryl groups include phenyl, naphthyl and biphenyl.
  • Substituted aryl groups include the above-described aryl groups which are substituted one or more times by halogen, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, and acyloxy (e.g., acetoxy).
  • Arylalkyl refers to an aryl-alkyl-radical in which the aryl and alkyl portions are in accordance with the previous descriptions. Suitable examples include 1-phenethyl, 2-phenethyl phenpropyl, phenbutyl, phenpentyl, and naphthylenemethyl. Also, in the case of R 3 , arylalkyl can be benzyl.
  • Arylalkenyl refers to an aryl-alkenyl-radical in which the aryl and alkenyl portions are in accordance with the previous descriptions of aryl and alkenyl. Suitable examples include 3-aryl-2-propenyl.
  • Heterocyclic groups refer to saturated, partially saturated and fully unsaturated heterocyclic groups having one or two rings and a total number of 5 to 10 ring atoms wherein at least one of the ring atoms is an N, O or S atom.
  • the heterocyclic group contains 1 to 3, especially 1 or 2, hetero-ring atoms selected from N, O and S, Suitable saturated and partially saturated heterocyclic groups include, but are not limited to tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, isoxazolinyl and the like.
  • Suitable heteroaryl groups include but are not limited to furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, pyridyl, pyrimidinyl, indolyl, quinolinyl, naphthyridinyl and the like.
  • Preferred heterocyclic and heteroaryl group's include tetrahydrofuranyl, tetrahydropyranyl, 2-thienyl, 3-thienyl, 2-, 3- or 4-pyridyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolinyl, and 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolinyl.
  • Substituted heterocyclic groups refer to the heterocyclic groups described above which are substituted in one or more places by halogen, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, and dialkylamino.
  • Heterocyclic-alkyl refers to a heterocyclic-alkyl-group wherein the heterocyclic and alkyl portions are in accordance with the previous discussions. Suitable examples are pyridylmethyl, thienylmethyl, pyrimidinylmethyl, pyrazinylmethyl, isoquinolinylmethyl, pyridylethyl and thienylethyl.
  • Partially unsaturated carbocyclic structures are non-aromatic monocyclic or bicyclic structures containing 5 to 14 carbon atoms, preferably 6 to 10 carbon atoms, wherein the ring structure(s) contains at least one C ⁇ C bond.
  • Suitable examples are cyclopentenyl, cyclohexenyl, tetrahydronaphthenyl and indan-2-yl.
  • Acyl refers to alkanoyl radicals having 1 to 13 carbon atoms in which the alkyl portion can be substituted by halogen, hydroxy, carboxy, alkyl, aryl and/or alkoxy; or aroyl radicals having 7 to 15 carbon atoms in which the aryl portion can be substituted by halogen, alkyl, alkoxy, nitro, carboxy and/or hydroxy.
  • Suitable acyl groups include formyl, acetyl, propionyl, butanoyl and benzoyl.
  • Substituted radicals preferably have 1 to 3 substituents, especially 1 to 2 substituents.
  • R 1 is preferably optionally substituted cycloalkyl, cycloalkylalkyl, aryl, heterocyclic, arylalkyl, or a partially unsaturated carbocyclic group, or is CHF 2 ; for example, CHF 2 , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl cyclopentylethyl, cyclopropylmethyl, phenyl, napthyl, phenethyl, phenpropyl, furanyl, pyrazinyl, pyrimidinyl, pyridyl, quinolinyl, isoquinolinyl, thienyl, indanyl, tetrahydrofuranyl, phenylpropenyl, substituted phenyl, and substituted phenethyl.
  • substituents are oxo, F, Cl, CF 3 , alkyl (such as methyl or ethyl), alkoxy (such as methoxy and ethoxy), CN, vinyl, methylenedioxy, COOH, and combinations thereof.
  • R 3 is other than H, R 1 is preferably cycloalkyl, cycloalkylalkyl or aryl, as well as CHF 2 , heterocyclic and arylalkyl. In such a case R 1 is especially optionally substituted cyclopentyl and phenethyl as well as 3-tetrahydrofuranyl, CHF 2 , and cyclopropylmethyl.
  • R 2 is preferably substituted or unsubstituted alkyl having 1 to 4 C atoms, most preferably CHF 2 and CH 3 .
  • R 3 is preferably H, substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl, CH 2 CONHR 5 or COR 4 , especially H, substituted benzyl- or CH 2 CONHR 5 .
  • R 3 groups include methyl, ethyl, propyl, n-butyl, methylbenzyl (e.g., 2-methylbenzyl), fluorobenzyl (e.g., 2-fluorobenzyl), difluorobenzyl (e.g., 2,3- or 2,6-difluorobenzyl), chlorobenzyl, methoxy, benzyl, cyanobenzyl, dichlorobenzyl, chlorofluorobenzyl, trifluoromethylbenzyl, and (CF 3 ) 2 benzyl.
  • methylbenzyl e.g., 2-methylbenzyl
  • fluorobenzyl e.g., 2-fluorobenzyl
  • difluorobenzyl e.g., 2,3- or 2,6-difluorobenzyl
  • chlorobenzyl methoxy, benzyl, cyanobenzyl, dichlorobenzyl, chlorofluorobenz
  • R 4 is preferably optionally substituted aryl such as phenyl, or is optionally substituted heterocyclic.
  • Preferred substituents for R 4 are F, Cl, CH 3 , C 2 H 5 , OCH 3 , COOH, and CN.
  • R 5 is preferably 2-methylphenyl, 2,6-dimethylphenyl, 2,3-difluorophenyl, 4-fluorophenyl, 4-pyridyl, 2-pyridyl, 6-methyl-2-pyridyl, 6-amino-2-pyridyl, 6-ethyl-2-pyridyl, 4,6-dimethyl-2-pyridyl, 6-bromo-2-pyridyl, 6-methyl-5-bromo-2-pyridyl, 2-methoxy-3-pyridyl, 4-CH 3 O—CO-3-pyridyl, and 2-cyano-3-pyridyl.
  • preferred PDE4 inhibitors in accordance with the invention are compounds described by subformulas Ia-Io which correspond to formula I but exhibit the following preferred groups:
  • the compound of formula I is selected from;
  • the compound can be in the form of a mixture of enantiomers such as the racemate or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.
  • the compound of formula I is selected from:
  • the compound can be in the form of a mixture of enantiomers such as the racemate, or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.
  • the compound of formula I is selected from:
  • the compound can be in the form of a mixture of enantiomers such as the racemate, or a mixture of diastereomers; or can be in the form of a single enantiomer or a single diastereomer.
  • Preferred aspects include pharmaceutical compositions comprising a compound of this invention and a pharmaceutically acceptable carrier and, optionally, another active agent as discussed below; a method of inhibiting a PDE4 enzyme, especially an isoenzyme, e.g., as determined by a conventional assay or one described herein, either in vitro or in vivo (in an animal, e.g., in an animal model, or hi a mammal or in a human); a method of treating a neurological syndrome, e.g., loss of memory, especially long-term memory, cognitive impairment or decline, memory impairment, etc.; a method of treating a disease state modulated by PDE4 activity, in a mammal, e.g., a human, e.g., those disease states mentioned herein.
  • a PDE4 enzyme especially an isoenzyme, e.g., as determined by a conventional assay or one described herein, either in vitro or in vivo (in an animal, e.g., in
  • the compounds of the present invention may be prepared conventionally, Some of the known processes that can be used are described below. All starting materials are known or can be conventionally prepared from known starting materials.
  • Methyl 4-nitro-3-(substituted-phenyl)butyrate was enantiomerically resolved by synthesizing diastereomeric phenethylamine amides as shown in scheme I. Nitro group reduction by catalytic hydrogenation as described by Demnitz, J. Molecules, 1998, 3, 107-119 was not successful. However, reduction of the diastereomerically pure nitro amides using NiCl 2 and NaBH 4 produced 90% yield of the corresponding diastereomerically pure amines.
  • 3-Aryloxy rolipram derivatives were prepared by cross coupling reaction with aryl boronic acids using a copper catalyst in the presence of an amine base.
  • Suitable copper catalysts include copper diacetate, copper (H) chloride, etc.
  • halogenated solvents are utilized such as chloroform, dichloromethane, 1,2-dichloroethane, and the like.
  • Commonly used bases include triethylamine, diisopropylamine, and pyrrolidine.
  • 3-phenyloxyrolipram can be prepared by Ullman type coupling starting with iodobenzene and 3-hydroxyrolipram as described previously (Schmiechen, R.; Horowski, R.; Palenschat, D.; Paschelke, G.; Wachtel, H.; Kehr, W., 4-(polyalkoxyphenyl)-2-pyrrolidones, U.S. Pat. No. 4,193,926, filed Mar. 18, 1980).
  • Compounds substituted at the 3-position with arylalkyl, alkyl, cycloalkyl, heteroalkyl or cycloalkylalkyl groups can be prepared by either Mitsunobu reaction between phenol 9 (R 1 ⁇ H) and alcohol or by an alkylation reaction between phenol 9 (R 1 ⁇ H) and R 1 X, where X is a suitable leaving group such as Cl, Br, methanesulphonyl, tosyloxy, etc.
  • alkylation reaction with alkyl halides, cycloalkyl halides, arylacyl chlorides, alpha bromoacetates, appropriately substituted alpha-bromides, and arylalkyl halides (i.e., benzylbromides) in polar aprotic solvents (i.e., DMF, THF, DMSO) using a non-nucleophilic base such as NaH or LDA, and a phase transfer catalyst such as 15-crown-5 ether.
  • polar aprotic solvents i.e., DMF, THF, DMSO
  • non-nucleophilic base such as NaH or LDA
  • phase transfer catalyst such as 15-crown-5 ether.
  • Reaction of methyl alpha-bromoacetate with a rolipram derivative as described above produces methyl N-acetates 12 (R ⁇ CH 3 ), which can be saponified to the acid 12 (R ⁇ H) by treatment with a base, such as NaOH or KOH, and then converted to the acid chloride 13 by any number of reagents, such as thionyl chloride or oxalyl chloride.
  • a base such as NaOH or KOH
  • reagents such as thionyl chloride or oxalyl chloride.
  • Such acid chlorides undergo reaction with a number of nucleophiles including anilines to provide compounds of type 14.
  • the acid 12 undergoes coupling reactions with amines and a suitable coupling reagent such as DCC or HBTU in the presence of an aprotic solvent such as dichloromethane or THF to produce amides of the type 14.
  • a suitable coupling reagent such as DCC or HBTU
  • an aprotic solvent such as dichloromethane or THF
  • R 5 is a protecting group such as benzyl this group can be selectively removed from 14 to give the corresponding (R 1 ⁇ H).
  • This phenol can then be substituted by common methods in the art such as by reaction with cyclopentyl bromide in the presence of a suitable base or by a Mitsunobu reaction with 3(S)-hydroxy-tetrahydrofuran to generate desired target compounds.
  • the optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, for example, by the formation of diastereoisomeric salts using an optically active acid or base or formation of covalent diastereomers.
  • appropriate acids are tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric and camphorsulfonic acid.
  • Mixtures of diastereoisomers can be separated into their individual diastereomers on the basis of their physical and/or chemical differences by methods known to those skilled in the art, for example, by chromatography or fractional crystallization.
  • the optically active bases or acids are then liberated from the separated diastereomeric salts.
  • a different process for separation of optical isomers involves the use of chiral chromatography (e.g., chiral HPLC columns), with or without conventional derivation, optimally chosen to maximize the separation of the enantiomers.
  • Suitable chiral HPLC columns are manufactured by Diacel, e.g., Chiracel OD and Chiracel OJ among many others, all routinely selectable.
  • Enzymatic separations, with or without derivitization, are also useful.
  • the optically active compounds of Formula I can likewise be obtained by utilizing optically active starting materials in chiral syntheses processes under reaction conditions which do not cause racemization.
  • the compounds can be used in different enriched isotopic forms, e.g., enriched in the content of 2 H, 3 H, 11 C, 13 C and/or 14 C.
  • the compounds are deuterated.
  • Such deuterated forms can be made the procedure described in U.S. Pat. Nos. 5,846,514 and 6,334,997.
  • deuteration can improve the efficacy and increase the duration of action of drugs.
  • Deuterium substituted compounds can be synthesized using various methods such as described in: Dean, Dennis C; Editor. Recent Advances in the Synthesis and Applications of Radiolabeled Compounds for Drug Discovery and Development, [In: Curr., Pharm. Des., 2000; 6(10)] (2000), 110 pp. CAN 133:68895 AN 2000:473538 CAPLUS; Kabalka, George W.; Varma, Rajender S. The synthesis of radiolabeled compounds VIA organometallic intermediates. Tetrahedron (1989), 45(21), 6601-21, CODEN: TETRAB ISSN:0040-4020. CAN 112:20527 AN 1990:20527 CAPLUS; and Evans, E. Anthony. Synthesis of radiolabeled compounds, J. Radioanal. Chem. (1981), 64(1-2), 9-32. CODEN: JRACBN ISSN:0022-4081, CAN 95:76229 AN 1981:476229 CAPLUS.
  • the present invention also relates to useful forms of the compounds as disclosed herein, such as pharmaceutically acceptable salts or prodrugs of all the compounds of the present invention for which salts or prodrugs can be prepared.
  • Pharmaceutically acceptable salts include, those obtained by reacting the main compound, functioning as a base, with an inorganic or organic acid to form a salt, for example, salts of hydrochloric acid, sulfuric acid, phosphoric acid, methane sulfonic acid, camphor sulfonic acid, oxalic acid, maleic acid, succinic acid and citric acid.
  • Pharmaceutically acceptable salts also include those in which the main compound functions as an acid and is reacted with an appropriate base to form, e.g., sodium, potassium, calcium, magnesium, ammonium, and choline salts.
  • an appropriate base e.g., sodium, potassium, calcium, magnesium, ammonium, and choline salts.
  • acid addition salts of the claimed compounds may be prepared by reaction of the compounds with the appropriate inorganic or organic acid via any of a number of known methods.
  • alkali and alkaline earth metal salts are prepared by reacting the compounds of the invention with the appropriate base via a variety of known methods.
  • acid salts that can be obtained by reaction with inorganic or organic acids: acetates, adipates, alginates, citrates, aspartates, benzoates, benzenesulfonates, bisulfates, butyrates, camphorates, digluconates, cyclopentanepropionates, dodecylsulfates, ethanesulfonates, glucoheptanoates, glycerophosphates, hemisulfates, heptanoates, hexanoates, fumarates, hydrobromides, hydroiodides, 2-hydroxy-ethanesulfonates, lactates, maleates, methanesulfonates, nicotinates, 2-naphthalenesulfonates, oxalates, palmoates, pectinates, persulfates, 3-phenylpropionates, picrates, pivalates, propionates,
  • the salts formed are pharmaceutically acceptable for administration to mammals.
  • pharmaceutically unacceptable salts of the compounds are suitable as intermediates, for example, for isolating the compound as a salt and then converting the salt back to the free base compound by treatment with an alkaline reagent.
  • the free base can then, if desired, be converted to a pharmaceutically acceptable acid addition salt.
  • the compounds of the invention can be administered alone or as an active ingredient of a formulation.
  • the present invention also includes pharmaceutical compositions of compounds of Formula I, containing, for example, one or more pharmaceutically acceptable carriers.
  • the compounds of the present invention can be administered to anyone requiring PDE4 inhibition.
  • Administration may be accomplished according to patient needs, for example, orally, nasally, parenterally (subcutaneously, intravenously, intramuscularly, intrasternally and by infusion) by inhalation, rectally, vaginally, topically and by ocular administration.
  • solid oral dosage forms can be used for administering compounds of the invention including such solid forms as tablets, gelcaps, capsules, caplets, granules, lozenges and bulk powders.
  • the compounds of the present invention can be administered alone or combined with various pharmaceutically acceptable carriers, diluents (such as sucrose, mannitol, lactose, starches) and excipients known in the art, including but not limited to suspending agents, solubilizers; buffering agents, binders, disintegrants, preservatives, colorants, flavorants, lubricants and the like.
  • Time release capsules, tablets and gels are also advantageous in administering the compounds of the present invention.
  • liquid oral dosage forms can also be used for administering compounds of the inventions, including aqueous and non-aqueous solutions, emulsions, suspensions, syrups, and elixirs.
  • Such dosage forms can also contain suitable inert diluents known in the art such as water and suitable excipients known in the art such as preservatives, wetting agents, sweeteners, flavorants, as well as agents for emulsifying and/or suspending the compounds of the invention.
  • the compounds of the present invention may be injected, for example, intravenously, in the form of an isotonic sterile solution. Other preparations are also possible.
  • Suppositories for rectal administration of the compounds of the present invention can be prepared by mixing the compound with a suitable excipient such as cocoa butter, salicylates and polyethylene glycols.
  • a suitable excipient such as cocoa butter, salicylates and polyethylene glycols.
  • Formulations for vaginal administration can be in the form of a pessary, tampon, cream, gel, paste, foam, or spray formula containing, in addition to the active ingredient, such suitable carriers as are known in the art.
  • the pharmaceutical composition can be in the form of creams, ointments, liniments, lotions, emulsions, suspensions, gels, solutions, pastes, powders, sprays, and drops suitable for administration to the skin, eye, ear or nose. Topical administration may also involve transdermal administration via means such as transdermal patches.
  • Aerosol formulations suitable for administering via inhalation also can be made.
  • the compounds according to the invention can be administered by inhalation in the form of a powder (e.g., micronized) or in the form of atomized solutions or suspensions.
  • the aerosol formulation can be placed into a pressurized acceptable propellant.
  • the compounds can be administered as the sole active agent or in combination with other pharmaceutical agents such as other agents used in the treatment of cognitive impairment and/or in the treatment of psychosis, e.g., other PDE4 inhibitors, calcium channel blockers, cholinergic drugs, adenosine receptor modulators, amphakines NMDA-R modulators, mGluR modulators, and cholinesterase inhibitors (e.g., donepezil, rivastigimine, and glanthanamine).
  • each active Ingredient can be administered either in accordance with their usual dosage range or a dose below their usual dosage range.
  • the present invention further includes methods of treatment that involve
  • the present invention includes methods of selective inhibition of PDE4 enzymes in animals, e.g., mammals, especially humans, wherein such inhibition has a therapeutic effect, such as where such inhibition may relieve conditions involving neurological syndromes, such as the loss of memory, especially long-term memory.
  • Such methods comprise administering to an animal in need thereof, especially a mammal, most especially a human, an inhibitory amount of a compound, alone or as part of a formulation, as disclosed herein.
  • the condition of memory impairment is manifested by impairment of the ability to learn new information and/or the inability to recall previously learned information.
  • Memory impairment is a primary symptom of dementia and can also be a symptom associated with such diseases as Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeld-Jakob disease, HIV, cardiovascular disease, and head trauma as well as age-related cognitive decline.
  • Dementias are diseases that include memory loss and additional intellectual impairment separate from memory.
  • the present invention includes methods for treating patients suffering from memory impairment in all forms of dementia.
  • Dementias are classified according to their cause and include: neurodegenerative dementias (Alzheimer's, Parkinson's disease, Pick's disease), vascular (Infarcts, Hemorrhage, Cardiac Disorders), mixed vascular and Alzheimer's, bacterial meningitis, Creutzfeld-Jacob Disease, and multiple sclerosis), traumatic (subdural hematoma or traumatic brain injury), infectious (HIV), toxic (heavy metals, alcohol, medications), metabolic (Vitamin B 12 or folate deficiency), CNS hypoxia, Cushing's disease, psychiatric (depression and schizophrenia) and hydrocephalus.
  • neurodegenerative dementias Alzheimer's, Parkinson's disease, Pick's disease
  • vascular Infarcts, Hemorrhage, Cardiac Disorders
  • the present invention also includes methods for treating memory loss separate from dementias, including mild cognitive impairment (MCI) and age-related cognitive decline.
  • MCI mild cognitive impairment
  • the present invention includes methods of treatment for memory impairment as a result of disease including Huntington's disease and Down's syndrome.
  • the invention includes methods for treating memory loss from anesthetics, chemotherapy, radiation treatment, and post-surgical trauma.
  • the compounds of the invention can also be used to treat schizophrenia, bipolar or manic depression, major depression, and drug addiction.
  • PDE4 inhibitors can be used to raise cAMP levels and prevent neurons from undergoing apoptosis.
  • PDE4 inhibitors are also known to be anti-inflammatory. The combination of preventing neuronal apoptosis and inhibiting inflammatory responses make these compounds useful to treat neurodegeneration resulting from any disease or injury, including stroke, Alzheimer's disease, multiple sclerosis, amyolaterosclerosis (ALS), and multiple systems atrophy (MSA).
  • the present invention includes methods of treating patients suffering from memory impairment due to, for example, mild cognitive impairment due to aging, Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeld-Jakob disease, depression, aging, head trauma, stroke, CNS hypoxia, cerebral senility, multiinfarct dementia and other neurological conditions, as well as HIV and cardiovascular diseases, comprising administering an effective amount of a compound according to formula (I) or a pharmaceutically acceptable salt thereof.
  • the compounds of the invention also exhibit anti-inflammatory activity.
  • inventive compounds are useful in the treatment of a variety of allergic and inflammatory diseases, particularly disease states characterized by decreased cyclic AMP levels and/or elevated phosphodiesterase 4 levels.
  • a method of treating allergic and inflammatory disease states comprising administering an effective amount of a compound according to formula (I) or a pharmaceutically acceptable salt thereof.
  • Such disease states include; asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD), atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, esoniophilic granuloma, psoriasis, inflammatory arthritis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, chronic glomerulonephritis, endotoxic shock, adult respiratory distress syndrome, cystic fibrosis, arterial restenosis, artherosclerosis, keratosis, rheumatoid spondylitis, osteoarthritis, pyresis, diabetes mellitus, pneumoconiosis, chronic obstructive airways disease, chronic obstructive pulmonary disease, toxic and allergic contact eczema, atopic eczema,
  • the compounds can also be used in a method of treating patients suffering from disease states characterized by decreased NMDA function, such as schizophrenia.
  • the compounds can also be used to treat psychosis characterized by elevated levels of PDE 4, for example, various forms of depression, such as manic depression, major depression, and depression associated with psychiatric and neurological disorders.
  • trisubstituted phenyl derivatives for treating asthma, chronic bronchitis, psoriasis, allergic rhinitis, and other inflammatory diseases, and for inhibiting tumor necrosis factor is known within the art. See, e.g., WO 98/58901, JP11-18957, IP 10-072415, WO 93/25517, WO 94/14742, U.S. Pat. No. 5,814,651, and U.S. Pat. No. 5,935,978. These references describe 1,3,4-trisubstituted phenyl compounds said to exhibit PDE4 inhibition activity. They also describe assays for determining PDE4 inhibition activity, and methods for synthesizing such compounds. The entire disclosures of these documents are hereby incorporated by reference.
  • PDE4 inhibitors may be used to prevent or ameliorate osteoporosis, as an antibiotic, for treatment of cardiovascular disease by mobilizing cholesterol from atherosclerotic lesions, to treat rheumatoid arthritis (RA), for long-term inhibition of mesenchymal-cell proliferation after transplantation, for treatment of urinary obstruction secondary to benign prostatic hyperplasia, for suppression of chemotaxis and reduction of invasion of colon cancer cells, for treatment of B cell chronic lymphocytic leukemia (B-CLL), for inhibition of uterine contractions, to attenuate pulmonary vascular ischemia-reperfusion injury (TRI), for corneal hydration, for inhibition of IL-2R expression and thereby abolishing HIV-1 DNA nuclear import into memory T cells, for augmentation of glucose-induced insulin secretion, in both the prevention and treatment of colitis, and to inhibit mast cell degranulation.
  • RA rheumatoid arthritis
  • RA rheumatoid arthritis
  • RA rheumatoi
  • the compounds of the present invention can be administered as the sole active agent or in combination with other pharmaceutical agents such as other agents used in the treatment of cognitive impairment and/or in the treatment of psychosis, e.g., other PDE4 inhibitors, calcium channel blockers, cholinergic drugs, adenosine receptor modulators, amphakines NMDA-R modulators, mGluR modulators, and cholinesterase inhibitors (e.g., donepezil, rivastigimine, and glanthanamine).
  • each active ingredient can be administered either in accordance with their usual dosage range or a dose below their usual dosage range.
  • the dosages of the compounds of the present invention depend upon a variety of factors including the particular syndrome to be treated, the severity of the symptoms, the route of administration, the frequency of the dosage interval, the particular compound utilized, the efficacy, toxicology profile, pharmacokinetic profile of the compound, and the presence of any deleterious side-effects, among other considerations.
  • the compounds of the invention are typically administered at dosage levels and in a mammal customary for PDE4 inhibitors such as those known compounds mentioned above.
  • the compounds can be administered, in single or multiple doses, by oral administration at a dosage level of generally 0.001-100 mg/ky/day, for example, 0.01-100 mg/kg/day, preferably 0.1-70 mg/kg/day, especially 0.5-10 mg/kg/day.
  • Unit dosage forms can contain generally 0.01-1000 mg of active compound, for example, 0.1-50 mg of active compound.
  • the compounds can be administered, in single or multiple dosages, at a dosage level of, for example, 0.001-50 mg/kg/day, preferably 0.001-10 mg/kg/day, especially 0.01-1 mg/kg/day.
  • Unit dosage forms can contain, for example, 0.1-10 mg of active compound.
  • buffers, media, reagents, cells, culture conditions and the like are not intended to be limiting, but are to be read so as to include all related materials that one of ordinary skill in the art would recognize as being of interest or value in the particular context in which that discussion is presented. For example, it is often possible to substitute one buffer system or culture medium for another and still achieve similar, if not identical, results. Those of skill in the art will have sufficient knowledge of such systems and methodologies so as to be able, without undue experimentation, to make such substitutions as will optimally serve their purposes in using the methods and procedures disclosed herein.
  • Diisopropylazodicarboxylate (63 mg, 0.6 mmol) is added to a solution of 4-(3-hydroxy-4-methoxyphenyl)-2-pyrrolidone (63 mg. 0.36 mmol), cinnamyl alcohol (43 mg, 0.3 mmol) and triphenyl phosphine (157 mg, 0.6 mmol) in 3 ml of tetrahydrofuran and the reaction mixture is stirred at 70° C.
  • Human PDE4 was obtained from baculovirus-infected Sf9 cells that expressed the recombinant enzyme.
  • the cDNA encoding hPDE-4D6 was subcloned into a baculovirus vector.
  • Insect cells (Sf9) were infected with the baculovirus and cells were cultured until protein was expressed.
  • the baculovirus-infected cells were lysed and the lysate was used as source of hPDE-4D6 enzyme.
  • the enzyme was partially purified using a DEAE ion exchange chromatography. This procedure can be repeated using cDNA encoding other PDE-4 enzymes.
  • Type 4 phosphodiesterases convert cyclic adenosine monophosphate (cAMP) to 5′-adenosine monophosphate (5′-AMP).
  • Nucleotidase converts 5′-AMP to adenosine. Therefore the combined activity of PDE4 and nucleotidase converts cAMP to adenosine.
  • Adenosine is readily separated from cAMP by neutral alumina columns.
  • Phosphodiesterase inhibitors block the conversion of cAMP to adenosine in this assay; consequently, PDE4 inhibitors cause a decrease in adenosine,
  • Cell lysates (40 ul) expressing hPDE-4D6 were combined with 50 ul of assay mix and 10 ul of inhibitors and incubated for 12 min at room temperature. Final concentrations of assay components were: 0.4 ug enzyme, 10 mM Tris-HCl (pH 7.5), 10 mM MgCl 2 , 3 uM cAMP, 0.002 U 5′-nucleotidase, and 3 ⁇ 10 4 cpm of [3H]cAMP.
  • the reaction was stopped by adding 100 ⁇ l of boiling 5 mN HCl. An aliquot of 75 ⁇ l of reaction mixture was transferred from each well to alumina columns (Multiplate; Millipore).
  • adenosine was eluted into an OptiPlate by spinning at 2000 rpm for 2 min; 150 ⁇ l per well of scintillation fluid was added to the OptiPlate. The plate was sealed, shaken for about 30 min, and cpm of [ 3 H]adenosine was determined using a Packard Topcount 96 counter.
  • test compounds are dissolved in 100% DMSO and diluted into the assay such that the final concentration of DMSO is 0.1%. DMSO does not affect enzyme activity at this concentration.
  • the test was performed as previously described (Zhang, H.-T., Crissman, A. M., Dorairaj, N. R., Chandler, L. J., and O'Donnell, J. M., Neuropsychopharmacology, 2000, 23, 198-204.).
  • the apparatus (Model E10-16SC, Coulbourn Instruments, Allentown, Pa.) consisted of a two-compartment chamber with an illuminated compartment connected to a darkened compartment by a guillotine door.
  • the floor of the darkened compartment consisted of stainless steel rods through which an electric foot-shock could be delivered from a constant current source.
  • the rat (Male Sprague-Dawley (Harlan) weighing 250 to 350 g) was placed in the illuminated compartment facing away from the closed guillotine door for 1 minute before the door was raised. The latency for entering the darkened compartment was recorded. After the rat entered the darkened compartment, the door was closed and a 0.5 mA electric shock was administered for 3 seconds. Twenty-four hours later, the rat was administered 0.1 mg/kg of the test compound or saline, 30 minutes prior to the injection of saline or test compound (dosed from 0.1 to 2.5 mg/kg, i.p.), which was 30 minutes before the retention test started. The rat was again placed in the illuminated compartment with the guillotine door open. The latency for entering the darkened compartment was recorded for up to 180 seconds, at which time the trial was terminated.
  • mice Male Sprague-Dawley (Harlan) weighing 250 to 350 g were placed in the eight-arm radial maze (each arm was 60 ⁇ 10 ⁇ 12 cm high; the maze was elevated 70 cm above the floor) for acclimation for two days.
  • Rats were then placed individually in the center of the maze for 5 minutes with food pellets placed close to the food wells, and then, the next day, in the wells at the end of the arms; 2 sessions a day were conducted. Next, four randomly selected arms were then baited with one pellet of food each. The rat was restricted to the center platform (26 cm in diameter) for 15 seconds and then allowed to move freely throughout the maze until it collected all pellets of food or 10 minutes passed, whichever came first.
  • test duration i.e., the time spent in the collection of all the pellets in the maze. If the working memory error was zero and the average reference memory error was less than one in five successive trials, the rats began the drug tests.
  • the test compound or saline was injected 15 minutes prior to vehicle or test agent, which was given 45 minutes before the test. Experiments were performed in a lighted room, which contained several extra-maze visual cues.
  • a decrease in adenosine concentration is indicative of inhibition of PDE activity. This procedure was used to screen compounds of the present invention for their ability to inhibit PDE4. pIC 50 values were determined by screening 6 to 12 concentrations of compound ranging from 0.1 nM to 10,000 nM and then plotting drug concentration versus 3 H-adenosine concentration. Prism® was used to estimate pIC 50 values.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Selective PDE4 inhibition is achieved by 4-(substituted-phenyl)-2-pyrrolidinone compounds. The compounds exhibit improved PDE4 inhibition as compared to compounds like rolipram and show selectivity with regard to inhibition of other classes of PDEs. The compounds of the present invention are of formula I:
Figure US20090176799A1-20090709-C00001
wherein R1, R2, and R3 are as defined herein.

Description

  • This application claims benefit of U.S. Provisional Application Ser. No. 60/329,314, filed Oct. 16, 2001, the entire disclosure of which is hereby incorporated by reference.
    • FIELD OF THE INVENTION
  • The present invention relates generally to the field of phosphodiesterase 4 (PDE4) enzyme inhibition. More specifically this invention relates to selective PDE4 inhibition by novel compounds, e.g., 4-(substituted-phenyl)-2-pyrrolidinone compounds, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
    • BACKGROUND OF THE INVENTION
  • The cyclic nucleotide specific phosphodiesterases (PDEs) represent a family of enzymes that catalyze the hydrolysis of various cyclic nucleoside monophosphates (including cAMP and cGMP). These cyclic nucleotides act as second messengers within cells, and as messengers, carry impulses from cell surface receptors having bound various hormones and neurotransmitters. PDEs act to regulate the level of cyclic nucleotides within cells and maintain cyclic nucleotide homeostasis by degrading such cyclic mononucleotides resulting in termination of their messenger role.
  • PDE enzymes can be grouped into eleven families according to their specificity toward hydrolysis of cAMP or cGMP, their sensitivity to regulation by calcium, calmodulin or cGMP, and their selective inhibition by various compounds. For example, PDE 1 is stimulated by Ca2+/calmodulin. PDE 2 is cGMP-dependent, and is found in the heart and adrenals. PDE 3 is cGMP-inhibited, and inhibition of this enzyme creates positive inotropic activity. PDE 4 is cAMP specific, and its inhibition causes airway relaxation, anti-inflammatory and antidepressant activity. PDE 5 appears to be important in regulating cGMP content in vascular smooth muscle, and therefore PDE 5 inhibitors may have cardiovascular activity. Since the PDEs possess distinct biochemical properties, it is likely that they are subject to a variety of different forms of regulation.
  • PDE4 is distinguished by various kinetic properties including low Michaelis constant for cAMP and sensitivity to certain drugs. The PDE4 enzyme family consists of four genes, which produce 4 isoforms of the PDE4 enzyme designated PDE4A, PDE4B, PDE4C, and PDE4D [See; Wang et al., Expression, Purification, and Characterization of human cAMP-Specific Phosphodiesterase (PDE4) Subtypes A, B, C, and D, Biochem. Biophys. Res. Comm., 234, 320-324 (1997)]. In addition, various splice variants of each PDE4 isoform have been identified.
  • PDE4 isoenzymes are localized in the cytosol of cells and are unassociated with any known membranous structures. PDE4 isoenzymes specifically inactivate cAMP by catalyzing its hydrolysis to adenosine 5′-monophosphate (AMP). Regulation of cAMP activity is important in many biological processes, including inflammation and memory, Inhibitors of PDE4 isoenzymes such as rolipram, piclamilast, CDP-840 and airflo are powerful anti-inflammatory agents and therefore may be useful in treating diseases where inflammation is problematic such as asthma or arthritis. Further, rolipram improves the cognitive performance of rats and mice in learning paradigms.
  • Figure US20090176799A1-20090709-C00002
  • In addition to such compounds as rolipram, xanthine derivatives such as pentoxifylline, denbufylline, and theophylline inhibit PDE4 and have received attention of late for their cognition enhancing effects, cAMP and cGMP are second messengers that mediate cellular responses to many different hormones and neurotransmitters. Thus, therapeutically significant effects may result from PDE inhibition and the resulting increase in intracellular cAMP or cGMP in key cells, such as those located in the nervous system and elsewhere in the body.
  • Rolipram, previously in development as an anti-depressant, selectively inhibits the PDE4 enzyme and has become a standard agent in the classification of PDE enzyme subtypes. Early work in the PDE4 field focused on depression and inflammation, and has subsequently been extended to include indications such as dementia, [see “The PDE IV Family Of Calcium-Phosphodiesterases Enzymes,” John A. Lowe, III, et al., Drugs of the Future 1992, 17(9):799-807 for a general review]. Further clinical developments of rolipram and other first-generation PDE4 inhibitors were terminated due to the side effect profile of these compounds. The primary side effect in primates is emesis, while the primary side effects in rodents are testicular degradation, weakening of vascular smooth muscle, psychotrophic effects, increased gastric acid secretion and stomach erosion. In humans, the primary side effect is nausea and emesis.
    • SUMMARY OF THE INVENTION
  • The present invention relates to novel compounds that inhibit, preferably selectively, PDE4 enzymes, and especially have improved side effect profiles, e.g., are relatively non-emetic (e.g., as compared to the previously discussed prior art compounds). In particular, the present invention relates to novel rolipram analogs. The compounds of this invention at the same time facilitate entry into cells, especially cells of the nervous system.
  • Still further, the present invention provides methods for synthesizing compounds with such activity and selectivity as well as methods of (and corresponding pharmaceutical compositions for) treating a patient, e.g., mammals, including humans, in need of PDE inhibition, especially PDE4 inhibition, for a disease state that involves elevated intracellular PDE 4 levels or decreased cAMP levels, e.g., involving neurological syndromes, especially those states associated with memory impairment, most especially long term memory impairment, as where such memory impairment is due at least in part to catabolism of intracellular cAMP levels by PDE 4 enzymes, or where such an impaired condition can be improved by increasing cAMP levels.
  • In a preferred aspect, the compounds of the inventions improve such diseases by inhibiting PDE4 enzymes at doses that do not induce emesis or other side effects.
  • Upon further study of the specification and appended claims, further aspects, objects and advantages of this invention will become apparent to those skilled in the art.
  • The present invention includes compounds of Formula I:
  • Figure US20090176799A1-20090709-C00003
  • wherein
      • X is O;
      • R1 is alkyl having 1 to 8 carbon atoms wherein optionally one or more —CH2CH2— groups are replaced in each case by —CH═CH— or —CC— groups,
        • alkyl having 1 to 8 carbon atoms which is substituted one or more times by halogen, oxo or combinations thereof wherein optionally one or more —CH2CH2— groups are replaced in each case by —CH═CH— or —C≡C— groups,
        • cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl having 1 to 4 carbon atoms or combinations thereof,
        • a heterocyclic group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom (e.g., 3-thienyl, 2-thienyl, 3-tetrahydrofuran), which is unsubstituted or substituted one of more times by halogen, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, dialkylamino or combinations thereof,
        • aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF3, OCF3, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido (e.g., acetamido), and acyloxy (e.g., acetoxy), or combinations thereof,
        • arylalkyl having 8 to 16 carbon atoms, which is unsubstituted or substituted preferably in the aryl portion, one or more times by halogen, CF3, OCF3, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido (e.g., acetamido), and acyloxy (e.g., acetoxy), or combinations thereof,
        • a partially unsaturated carbocyclic group having 5 to 14 carbon atoms, (e.g., cyclohexenyl, cyclohexadienyl, indanyl, and tetrahydronaphthenyl), which is unsubstituted or substituted one or more times by halogen, alkyl, alkoxy, nitro, cyano, oxo, or combinations thereof,
        • arylalkenyl having 8 to 16 carbon atoms, wherein the alkenyl portion has up to 5 carbon atoms, which is unsubstituted or substituted preferably in the aryl portion, one or more times by halogen, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl; alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido (e.g., acetamido), and acyloxy (e.g., acetoxy), or combinations thereof;
        • a heterocyclic-alkyl group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, which is unsubstituted or substituted one or more times in the heteroaryl portion by halogen, aryl, alkyl, alkoxy/cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, dialkylamino, carboxy or combinations thereof and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof, or
        • cycloalkylalkyl having 4 to 16 carbon atoms (e.g., cyclopentylethyl and cyclopropylmethyl), which is unsubstituted or substituted one or more times by halogen, oxo, alkyl or combinations thereof,
      • R2 is alkyl having 1 to 4 carbon atoms, which is unsubstituted or substituted one or more times by halogen;
      • R3 is H,
        • alkyl having 1 to 8 carbon atoms wherein optionally one or more —CH2CH2— groups are replaced in each case by CH═CH— or —CC— groups,
        • alkyl having 1 to 8 carbon atoms which is substituted one or more times by halogen, oxo, or combinations thereof wherein optionally one or more —CH2CH2— groups are replaced in each case by —CH═CH— or —CC— groups,
        • cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl, or combinations thereof,
        • arylalkyl having 7 to 16 carbon atoms, which is unsubstituted or substituted preferably in the aryl portion, one or more times by halogen, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, and acyloxy (e.g., acetoxy), or combinations thereof,
        • heterocyclic-alkyl group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, which is unsubstituted or substituted one or more tunes in the heteroaryl portion by halogen, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, dialkylamino, carboxy or combinations thereof and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof,
        • alkoxyalkyl having 3 to 8 carbon atoms,
        • —C(O)R4, or
        • —CH2CONHR5;
      • R4 is alkyl having 1 to 12 carbon atoms wherein optionally one or more —CH2CH2— groups are replaced in each case by —CH═CH— or —C≡C— groups,
        • alkyl having 1 to 12 carbon atoms which is substituted one or more times by halogen, oxo, or combinations thereof wherein optionally one or more —CH2CH2— groups are replaced in each case by —CH═CH— or —C≡C— groups,
        • cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl, or combinations thereof,
        • cycloalkylalkyl having 4 to 16 carbon atoms (e.g., cyclopentylethyl and cyclopropylmethyl), which is unsubstituted or substituted one or more times by halogen, oxo, alkyl or combinations thereof,
        • aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF3, OCF3, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido (e.g., acetamido), and acyloxy (e.g., acetoxy), or combinations thereof,
        • arylalkyl having 8 to 16 carbon atoms, which is unsubstituted or substituted preferably in the aryl portion, one or more times by halogen, CF3, OCF3, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido (e.g., acetamido), and acyloxy (e.g., acetoxy), or combinations thereof,
        • a heterocyclic group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom (e.g., 3-thienyl, 2-thienyl, 3-tetrahydrofuran), which is unsubstituted or substituted one or more times by halogen, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof, or
        • a heterocyclic-alkyl group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, which is unsubstituted or substituted one or more times in the heteroaryl portion by halogen, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, dialkylamino, carboxy or combinations thereof and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof; and
      • R5 is H,
        • alkyl having 1 to 12 carbon atoms wherein optionally one or more —CH2CH2— groups are replaced in each case by —CH═CH— or —CC— groups,
        • alkyl having 1 to 12 carbon atoms which is substituted one or more times by halogen, oxo, or combinations thereof wherein optionally one or more —CH2CH2— groups are replaced in each case by —CH═CH— or —CC— groups,
        • cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl, or combinations thereof,
        • cycloalkylalkyl having 4 to 16 carbon atoms (e.g., cyclopentylethyl and cyclopropylmethyl), which is unsubstituted or substituted one or more times by halogen, oxo, alkyl or combinations thereof,
        • aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF3, OCF3, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido (e.g., acetamido), and acyloxy (e.g., acetoxy), or combinations thereof,
        • arylalkyl having 8 to 16 carbon atoms, which is unsubstituted or substituted preferably in the aryl portion, one or more times by halogen, CF3, OCF3, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido (e.g., acetamido), and acyloxy (e.g., acetoxy), or combinations thereof,
        • a heterocyclic group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom (e.g., 3-thienyl, 2-thienyl, 3-tetrahydrofuran), which is unsubstituted or substituted one or more times by halogen, aryl, alkyl, alkoxy, alkoxycarbonyl, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof, or
        • a heterocyclic-alkyl group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, which is unsubstituted or substituted one or more times in the heteroaryl portion by halogen, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, dialkylamino, carboxy or combinations thereof and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof;
          • with the proviso that:
            • (a) when X is O, R2 is CH3 and R3 is H, then R1 is not methyl, ethyl, n-propyl, isopropyl, sec-butyl, n-butyl, isobutyl, neopentyl, n-pentyl, 2-methylbutyl, isopentyl, n-hexyl, phenyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl, methylcyclopentyl, cyclopropylmethyl, cyclopentylmethyl, 2-propenyl, 2-propynyl, 3-methyl-2-butenyl, N-substituted 2-piperazinylethyl, norbornyl, 3-tetrahydrofuryl, 2-tetrahydrofuryl, 3-tetrahydrothienyl, 2-oxacyclopropyl, 2-oxacyclopenyl, 3-oxacyclopentyl, 2-chloroethyl, 2-bromoethyl, 2,2,2-trifluoroethyl, 3-bromopropyl, 3-chloropropyl, or 4-bromobutyl;
            • (b) when X is O, R1 is cyclopentyl, and R2 is methyl, then R3 is not H, acetyl, benzyl, 4-hydroxybenzyl, 4-acetoxybenzyl, 4-bromobenzyl, 3,4-dimethoxybenzyl, 4-methylthiobenzyl, 4-cyanobenzyl, 2-aminobenzyl, 3-aminobenzyl, 4-aminobenzyl, 4-dimethylaminobenzyl, 2,4-diaminobenzyl, 4-amino-3,5-dimethoxybenzyl, 3-carboxybenzyl, 3-methoxycarbonylbenzyl, 4-methoxycarbonylbenzyl, 4-methylsulfinylbenzyl, 4-methylsulfonylbenzyl, 2-nitrobenzyl, 3-nitrobenzyl, 4-nitrobenzyl, 2,4-dinitrobenzyl, 2-nitro-4-aminobenzyl, 2-amino-4-nitrobenzyl, morpholinoethyl, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 4-(6-fluoroquinolyl)methyl, 2-(7-chloroquinolyl)methyl, 2-imidazoylmethyl, or substituted imidazoylmethyl,
            • (c) when X is O, R1 is CH3, and R5 is H, then R2 is not methyl, ethyl, or butyl.
            • (d) when X is O and R3 is H, then R1 and R2 are not both ethyl or isobutyl.
            • (e) When X is O, and R1 and R2 are both difluoromethyl, then R3 is not 4-aminobenzyl, or 4-amino-3,5-dimethoxybenzyl.
  • In accordance with the method aspect of the invention, there is provided a method of treating a patient (e.g., a mammal such as a human) suffering from a disease state (e.g., memory impairment) involving decreased cAMP levels and/or increased intracellular PDE4 levels, comprising administering to the patient a compound according to formula I′:
  • Figure US20090176799A1-20090709-C00004
  • wherein
      • X is O;
      • R1 is alkyl having 1 to 8 carbon atoms wherein optionally one or more —CH2CH2— groups are replaced in each case by —CH═CH— or —CC— groups,
        • alkyl having 1 to 8 carbon atoms which is substituted one or more times by halogen, oxo or combinations thereof wherein optionally one or more —CH2CH2— groups are replaced in each case by —CH═CH— or —CC— groups,
        • cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl having 1 to 4 carbon atoms, or combinations thereof,
        • a heterocyclic group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom (e.g., 3-thienyl, 2-thienyl, 3-tetrahydrofuran), which is unsubstituted or substituted one or more times by halogen, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof,
        • aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF3, OCF3, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido (e.g., acetamido), and acyloxy (e.g., acetoxy), or combinations thereof,
        • arylalkyl having 8 to 16 carbon atoms, which is unsubstituted or substituted preferably in the aryl portion, one or more times by halogen, CF3, OCF3, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido (e.g., acetamido), and acyloxy (e.g., acetoxy), or combinations thereof,
        • a partially unsaturated carbocyclic group, having 5 to 14 carbon atoms, (e.g., cyclohexenyl, cyclohexadienyl, indanyl, and tetrahydronaphthenyl), which is unsubstituted or substituted one or more times by halogen, alkyl, alkoxy, nitro, cyano, oxo, or combinations thereof, arylalkenyl having 8 to 16 carbon atoms, wherein the alkenyl portion has up to 5 carbon atoms, which is unsubstituted or substituted preferably in the aryl portion, one or more times by halogen, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido (e.g., acetamido), and acyloxy (e.g., acetoxy), or combinations thereof;
        • a heterocyclic-alkyl group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom which is unsubstituted or substituted one or more times in the heteroaryl portion by halogen, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, dialkylamino, carboxy or combinations thereof and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof, or
        • cycloalkylalkyl having 4 to 16 carbon atoms (e.g., cyclopentylethyl and cyclopropylmethyl), which is unsubstituted or substituted one or more times by halogen, oxo, alkyl or combinations thereof,
      • R2 is alkyl having 1 to 4 carbon atoms, which is unsubstituted or substituted one or more times by halogen;
      • R3 is H,
        • alkyl having 1 to 8 carbon atoms wherein optionally one or more —CH2CH2— groups are replaced in each case by —CH═CH— or —CC— groups,
        • alkyl having 1 to 8 carbon atoms which is substituted one or more times by halogen, oxo, or combinations thereof wherein optionally one or more —CH2CH2— groups are replaced in each case by —CH═CH— or —CC— groups,
        • cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl, or combinations thereof,
        • arylalkyl having 7 to 16 carbon atoms, which is unsubstituted or substituted preferably in the aryl portion, one or more times by halogen, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, and acyloxy (e.g., acetoxy), or combinations thereof,
        • heterocyclic-alkyl group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, which is unsubstituted or substituted one or more times in the heteroaryl portion by halogen, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, dialkylamino carboxy or combinations thereof and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof,
        • alkoxyalkyl having 3 to 8 carbon atoms,
        • —C(O)R4, or
        • —CH2CONHR5;
      • R4 is alkyl having 1 to 12 carbon atoms wherein optionally one or more —CH2CH2— groups are replaced in each case by —CH═CH— or —C≡C— groups,
        • alkyl having 1 to 12 carbon atoms which is substituted one or more times by halogen, oxo, or combinations thereof wherein optionally one or more —CH2CH2— groups are replaced in each case by —CH═CH— or —C≡C— groups,
        • cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl, or combinations thereof,
        • cycloalkylalkyl having 4 to 16 carbon atoms (e.g., cyclopentylethyl and cyclopropylmethyl), which is unsubstituted or substituted one or more times by halogen, oxo, alkyl or combinations thereof,
        • aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF3, OCF3, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido (e.g., acetamido), and acyloxy (e.g., acetoxy), or combinations thereof,
        • arylalkyl having 8 to 16 carbon atoms, which is unsubstituted or substituted preferably in the aryl portion, one or more times by halogen, CF3, OCF3, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido (e.g., acetamido), and acyloxy (e.g., acetoxy), or combinations thereof,
        • a heterocyclic group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least i ring atom is a N, O or S atom (e.g., 3-thienyl, 2-thienyl, 3-tetrahydrofuran), which is unsubstituted or substituted one or more times by halogen, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof, or
        • a heterocyclic-alkyl group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, which is unsubstituted or substituted one or more times in the heteroaryl portion by halogen, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, dialkylamino, carboxy or combinations thereof and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof; and
      • R5 is H,
        • alkyl having 1 to 12 carbon atoms wherein optionally one or more —CH2CH2— groups are replaced in each case by —CH═CH— or —CC— groups,
        • alkyl having 1 to 12 carbon atoms which is substituted one or more times by halogen, oxo, or combinations thereof wherein optionally one or more —CH2CH2— groups are replaced in each case by —CH═CH— or —CC— groups,
        • cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl, or combinations thereof,
        • cycloalkylalkyl having 4 to 16 carbon atoms (e.g., cyclopentylethyl and cyclopropylmethyl), which is unsubstituted or substituted one or more times by halogen, oxo, alkyl or combinations thereof,
        • aryl having 6 to 14 carbon atoms, which is unsubstituted or unsubstituted or substituted one or more times by halogen, CF3, OCF3, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido (e.g., acetamido), and acyloxy (e.g., acetoxy), or combinations thereof; and
        • arylalkyl having 8 to 16 carbon atoms, which is unsubstituted or substituted preferably in the aryl portion, one or more times by halogen, CF3, OCF3, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido (e.g., acetamido), and acyloxy (e.g., acetoxy), or combinations thereof,
        • a heterocyclic group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom (e.g., 3-thienyl, 2-thienyl, 3-tetrahydrofuran), which is unsubstituted or substituted one or more times by halogen, aryl, alkyl; alkoxy, alkoxycarbonyl, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof,
        • a heterocyclic-alkyl group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, which is unsubstituted or substituted one or more times in the heteroaryl portion by halogen, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, dialkylamino, carboxy or combinations thereof and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof.
  • The compounds of the present invention are effective in inhibiting, or modulating the activity of PDE4 in animals, e.g., mammals, especially humans. These compounds exhibit neurological activity, especially where such activity affects cognition, including long term memory. These compounds will also be effective in treating diseases where decreased cAMP levels are involved. This includes but is not limited to inflammatory diseases. These compounds may also function as antidepressants, or be useful in treating cognitive and negative symptoms of schizophrenia.
  • Assays for determining PDE 4 inhibiting activity, selectivity of PDE4 inhibiting activity, and selectivity of inhibiting PDE 4 isoenzymes are known within the art. See, e.g., U.S. Pat. No. 6,136,821, the disclosure of which is incorporated herein by reference.
  • Halogen herein refers to F, Cl, Br, and I. Preferred halogens are F and Cl.
  • Alkyl means a straight-chain or branched-chain aliphatic hydrocarbon radical. In the case of R1 and R3 suitable alkyl groups have preferably 1 to 8 carbon atoms, especially 1 to 4 carbon atoms. In the case of R2, suitable alkyl groups have preferably 1 to 4 carbon atoms. In the case of R4 and R5, suitable alkyl groups have preferably 1 to 12 carbon atoms, especially 1 to 8 carbon atoms, in particular 1 to 4 carbon atoms.
  • Suitable alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, and dodecyl. Other examples of suitable alkyl groups include 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, ethylmethylpropyl, trimethylpropyl, methylhexyl, dimethylpentyl, ethylpentyl, ethylmethylbutyl, dimethylbutyl, and the like.
  • These alkyl radicals can optionally have one or more —CH2CH2— groups replaced in each case by —CH═CH— or —CC— groups. Suitable alkenyl or alkynyl groups are 1-propenyl, 2-propenyl, 1-propynyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-butynyl, 1,3-butadienyl and 3-methyl-2-butenyl.
  • The substituted alkyl groups for R1, R3, R4 and R5 are alkyl groups as described above which are substituted in one or more positions by halogens and/or oxo. Halogens are preferred substituents, especially F and Cl. For R2, the substituted alkyl groups have 1 to 4 carbon atoms and are substituted one or more times by halogen, especially F and Cl, e.g., C1-C4 alkyl substituted by up to five F atoms.
  • In the arylalkyl groups, heterocyclic-alkyl groups, cycloalkyl-alkyl groups and alkoxyalkyl groups, “alkyl” refers to a divalent alkylene group having in general up to about 13 carbon atoms. In the case of the arylalkyl group for R1, the “alkyl” portion has preferably 2 to 10 carbon atoms. In the case of other arylalkyl groups, the “alkyl” portion has preferably 1 to 10. In the heterocyclic-alkyl groups, the “alkyl” portion preferably has 1 to 12 carbon atoms. In the alkoxyalkyl groups, the “alkyl” portion preferably has 2 to 7 carbon atoms. In the cycloalkylalkyl groups, the “alkyl” portion preferably has 1 to 13 carbon atoms.
  • In the cases where alkyl is a substituent (e.g., alkyl substituents on aryl and heterocyclic groups) or is part of a substituent (e.g., in the alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, alkylthio, alkylsulphinyl, and alkylsulphonyl substituents for aryl), the alkyl portion preferably has 1 to 12 carbon atoms, especially 1 to 8 carbon atoms, in particular 1 to 4 carbon atoms.
  • Alkoxy means alkyl-O— groups in which the alkyl portion has 1 to 8 carbon atoms. Suitable alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, isobutoxy, sec-butoxy, pentoxy, hexoxy, heptoxy, octoxy, and trifluoromethoxy. Preferred alkoxy groups are methoxy and ethoxy. The alkoxyalkyl group for R3 preferably has 3 to 8 carbon atoms, e.g., methoxyethyl.
  • Similarly, alkoxycarbonyl means an alkyl-O—CO— group in which the alkyl portion has 1 to 8 carbon atoms.
  • Alkenyl refers to straight-chain or branched-chain aliphatic radicals containing 2 to 12 carbon atoms in which one or more —CH2—CH2— structures is replaced by —CH═CH—. Suitable alkenyl groups are ethenyl, 1-propenyl, 2-methylethenyl, 1-butene, 2-butene, 1-pentenyl, and 2-pentenyl. In the arylalkenyl groups, alkenyl refers to an alkyenylene group having preferably 2 to 5 carbon atoms.
  • Cycloalkyl means a monocyclic, bicyclic or tricyclic saturated hydrocarbon radical having 3 to 8 carbon atoms, preferably 4 to 6 carbon atoms, especially 5 carbon atoms. Suitable cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and norbornyl. Other suitable cycloalkyl groups include spiropentyl, bicyclo[2.1.0]pentyl, bicyclo[3.1.0]hexyl, spiro[2.4]heptyl, spiro[2.5]octyl, bicyclo[5.1.0]octyl, spiro[2.6]nonyl, bicyclo[2.2.0]hexyl, spiro[3.3]heptyl, and bicyclo[4.2.0]octyl. The preferred cycloalkyl group is cyclopentyl.
  • The cycloalkyl group can be substituted by halogens, oxo and/or alkyl. Halogens and/or alkyl groups are preferred substituents.
  • Cycloalkylalkyl refers to a cycloalkyl-alkyl-radical in which the cycloalkyl and alkyl portions are in accordance with the previous descriptions. Suitable examples include cyclopentylethyl and cyclopropylmethyl.
  • Aryl, as a group or substituent per se or as part of a group or substituent, refers to an aromatic carbocyclic radical containing 6 to 14 carbon atoms, preferably 6 to 12 carbon atoms, especially 6 to 10 carbon atoms. Suitable aryl groups include phenyl, naphthyl and biphenyl. Substituted aryl groups include the above-described aryl groups which are substituted one or more times by halogen, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, and acyloxy (e.g., acetoxy).
  • Arylalkyl refers to an aryl-alkyl-radical in which the aryl and alkyl portions are in accordance with the previous descriptions. Suitable examples include 1-phenethyl, 2-phenethyl phenpropyl, phenbutyl, phenpentyl, and naphthylenemethyl. Also, in the case of R3, arylalkyl can be benzyl.
  • Arylalkenyl refers to an aryl-alkenyl-radical in which the aryl and alkenyl portions are in accordance with the previous descriptions of aryl and alkenyl. Suitable examples include 3-aryl-2-propenyl.
  • Heterocyclic groups refer to saturated, partially saturated and fully unsaturated heterocyclic groups having one or two rings and a total number of 5 to 10 ring atoms wherein at least one of the ring atoms is an N, O or S atom. Preferably, the heterocyclic group contains 1 to 3, especially 1 or 2, hetero-ring atoms selected from N, O and S, Suitable saturated and partially saturated heterocyclic groups include, but are not limited to tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, isoxazolinyl and the like. Suitable heteroaryl groups include but are not limited to furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, pyridyl, pyrimidinyl, indolyl, quinolinyl, naphthyridinyl and the like. Preferred heterocyclic and heteroaryl group's include tetrahydrofuranyl, tetrahydropyranyl, 2-thienyl, 3-thienyl, 2-, 3- or 4-pyridyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolinyl, and 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolinyl.
  • Substituted heterocyclic groups refer to the heterocyclic groups described above which are substituted in one or more places by halogen, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, and dialkylamino.
  • Heterocyclic-alkyl refers to a heterocyclic-alkyl-group wherein the heterocyclic and alkyl portions are in accordance with the previous discussions. Suitable examples are pyridylmethyl, thienylmethyl, pyrimidinylmethyl, pyrazinylmethyl, isoquinolinylmethyl, pyridylethyl and thienylethyl.
  • Partially unsaturated carbocyclic structures are non-aromatic monocyclic or bicyclic structures containing 5 to 14 carbon atoms, preferably 6 to 10 carbon atoms, wherein the ring structure(s) contains at least one C═C bond. Suitable examples are cyclopentenyl, cyclohexenyl, tetrahydronaphthenyl and indan-2-yl.
  • Acyl refers to alkanoyl radicals having 1 to 13 carbon atoms in which the alkyl portion can be substituted by halogen, hydroxy, carboxy, alkyl, aryl and/or alkoxy; or aroyl radicals having 7 to 15 carbon atoms in which the aryl portion can be substituted by halogen, alkyl, alkoxy, nitro, carboxy and/or hydroxy. Suitable acyl groups include formyl, acetyl, propionyl, butanoyl and benzoyl.
  • Substituted radicals preferably have 1 to 3 substituents, especially 1 to 2 substituents.
  • R1 is preferably optionally substituted cycloalkyl, cycloalkylalkyl, aryl, heterocyclic, arylalkyl, or a partially unsaturated carbocyclic group, or is CHF2; for example, CHF2, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl cyclopentylethyl, cyclopropylmethyl, phenyl, napthyl, phenethyl, phenpropyl, furanyl, pyrazinyl, pyrimidinyl, pyridyl, quinolinyl, isoquinolinyl, thienyl, indanyl, tetrahydrofuranyl, phenylpropenyl, substituted phenyl, and substituted phenethyl. Preferred substituents are oxo, F, Cl, CF3, alkyl (such as methyl or ethyl), alkoxy (such as methoxy and ethoxy), CN, vinyl, methylenedioxy, COOH, and combinations thereof. When R3 is other than H, R1 is preferably cycloalkyl, cycloalkylalkyl or aryl, as well as CHF2, heterocyclic and arylalkyl. In such a case R1 is especially optionally substituted cyclopentyl and phenethyl as well as 3-tetrahydrofuranyl, CHF2, and cyclopropylmethyl.
  • R2 is preferably substituted or unsubstituted alkyl having 1 to 4 C atoms, most preferably CHF2 and CH3.
  • R3 is preferably H, substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl, CH2CONHR5 or COR4, especially H, substituted benzyl- or CH2CONHR5. Examples of suitable R3 groups include methyl, ethyl, propyl, n-butyl, methylbenzyl (e.g., 2-methylbenzyl), fluorobenzyl (e.g., 2-fluorobenzyl), difluorobenzyl (e.g., 2,3- or 2,6-difluorobenzyl), chlorobenzyl, methoxy, benzyl, cyanobenzyl, dichlorobenzyl, chlorofluorobenzyl, trifluoromethylbenzyl, and (CF3)2 benzyl.
  • R4, if present, is preferably optionally substituted aryl such as phenyl, or is optionally substituted heterocyclic. Preferred substituents for R4 are F, Cl, CH3, C2H5, OCH3, COOH, and CN.
  • R5, if present, is preferably 2-methylphenyl, 2,6-dimethylphenyl, 2,3-difluorophenyl, 4-fluorophenyl, 4-pyridyl, 2-pyridyl, 6-methyl-2-pyridyl, 6-amino-2-pyridyl, 6-ethyl-2-pyridyl, 4,6-dimethyl-2-pyridyl, 6-bromo-2-pyridyl, 6-methyl-5-bromo-2-pyridyl, 2-methoxy-3-pyridyl, 4-CH3O—CO-3-pyridyl, and 2-cyano-3-pyridyl.
  • In addition, preferred PDE4 inhibitors in accordance with the invention are compounds described by subformulas Ia-Io which correspond to formula I but exhibit the following preferred groups:
      • Ia R2 is CH3 or CHF2.
      • Ib R2 is CH3 or CHF2, and
        • R3 is H.
      • Ic R3 is H; and
        • R1 is optionally substituted cycloalkyl, heterocyclic group, heterocyclic alkyl group, arylalkyl or cycloalkylalkyl, or is CHF2.
      • Id R2 is CH3 or CHF2;
        • R1 is cyclopentyl, tetrahydrofuran, or cyclopropylmethyl, as well as CHF2 and phenethyl; and
        • R3 is not H.
      • Ie R2 is CH3 or CHF2
        • R3 is H; and
        • R1 is phenethyl which is unsubstituted or the phenyl portion is substituted by F, Cl, Br, I, CN, C1-4-alkyl and/or C1-4-alkoxy, phenpropyl which is unsubstituted or the phenyl portion is substituted by F, Cl, Br, I, CN, C1-4-alkyl and/or C1-4-alkoxy, phenylbutyl which is unsubstituted or the phenyl portion is substituted by F, Cl, Br, I, CN, CM-alkyl and/or C1-4-alkoxy, or 3-phenyl-2-propenyl.
      • If R1 is 3(R)-tetrahydrofuramyl;
        • R2 is CH3 or CHF2; and
        • R3 is arylalkyl in which the aryl group is substituted by F, Br, Cl, I, alkyl or alkoxy.
      • Ig R1 is cycloalkyl;
        • R2 is CH3 or CHF2; and
        • R3 is arylalkyl in which the aryl group is substituted by F, Br, Cl, I, alkyl or alkoxy.
      • Ih R1 is cyclopentyl, tetrahydrofuran, or cyclopropylmethyl, as well as CHF2 and phenethyl;
        • R2 is CH3 or CHF2; and
        • R3 is arylalkyl in which the aryl group is substituted by F, Br, Cl, I, alkyl or alkoxy.
      • Ii R1 is cyclopentyl, tetrahydrofuran, cyclopropylmethyl or CHF2, as well as phenethyl;
        • R2 is CH3 or CHF2; and
        • R3 is methylbenzyl, methoxybenzyl, chlorobenzyl, fluorobenzyl, trifluorobenzyl, difluorobenzyl, dichlorobenzyl, fluorochlorobenzyl, or bis(trifluoromethyl)benzyl.
      • Ij R1 is cycloalkyl, heterocyclic group, or heterocyclic alkyl group, as well as CHF2, cycloalkylalkyl, and arylalkyl;
        • R2 is CHF3 or CHF2; and
        • R3 is CH2CONHR5.
      • Ik R1 is cyclopentyl, tetrahydrofuran, or cyclopropylmethyl, as well as CHF2 and phenethyl;
        • R2 is CH3 or CHF2; and
        • R3 is CH2CONHR5.
      • Il R1 is cycloalkyl, heterocyclic group, or heterocyclicalkyl group, as well as CHF2 and cycloalkylalkyl;
        • R2 is CH3 or CHF2;
        • R3 is CH2CONHR5; and
        • R5 is substituted or unsubstituted phenyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl.
      • Im R1 is cycloalkyl, heterocyclic group, or heterocyclicalkyl group, as well as CHF2 and cycloalkylalkyl;
        • R2 is CH3 or CHF2;
        • R3 is CH2CONHR5; and
        • R5 is 2-methylphenyl, 2,6-dimethylphenyl, 2,3-difluorophenyl, 4-fluorophenyl, 4-pyridyl, 2-pyridyl, 6-methyl-2-pyridyl, 6-amino-2-pyridyl, 6-ethyl-2-pyridyl, 4,6-dimethyl-2-pyridyl, 6-bromo-2-pyridyl, 6-methyl-5-bromo-2-pyridyl, 2-methoxy-3-pyridyl, 4-CH3O—CO-3-pyridyl, and 2-cyano-3-pyridyl.
      • In R1 is cyclopentyl, tetrahydrofuran, or cyclopropylmethyl as well as CHF2;
        • R2 is CH3 or CHF2;
        • R3 is CH2CONHR3; and
        • R5 is substituted or unsubstituted phenyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl.
      • Io R1 is cyclopentyl, tetrahydrofuran, or cyclopropylmethyl, as well as CHF2;
        • R2 is CH3 or CHF2;
        • R3 is CH2CONHR5; and
        • R5 is 2-methylphenyl, 2,6-dimethylphenyl, 2,3-difluorophenyl, 4-fluorophenyl, 4-pyridyl, 2-pyridyl, 6-methyl-2-pyridyl, 6-amino-2-pyridyl, 6-ethyl-2-pyridyl, 4,6-dimethyl-2-pyridyl, 6-bromo-2-pyridyl, 6-methyl-5-bromo-2-pyridyl, 2-methoxy-3-pyridyl, 4-CH3O—CO-3-pyridyl, and 2-cyano-3-pyridyl.
  • According to a further preferred compound aspect of the invention, the compound of formula I is selected from;
    • 4-[4-Methoxy-3-(4-methoxyphenoxy)phenyl]-2-pyrrolidone,
    • 4-[4-Methoxy-3-(3-thienyloxy)phenyl]-2-pyrrolidone,
    • 4-[3-(4-Fluorophenoxy)-4-methoxyphenyl]-2-pyrrolidone,
    • 4-(3-(3-Cyclohexyl-1-propyloxy)-4-methoxyphenyl)-2-pyrrolidone,
    • 4-(4-Methoxy-3-(2-phenylethoxy)phenyl)-2-pyrrolidone,
    • 4-(4-Methoxy-3-(3-phenyl-1-propoxy)phenyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-chloro-4-fluorobenzyl)-2-pyrrolidone,
    • Methyl 4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone-1-acetate,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-cyanomethyl-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-cyclopentyl-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(4-methoxybenzoyl)-2-pyrrolidone,
    • 4(S)-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-1-(N-(2-(6-methylpyridyl))-aminocarbonylmethyl)-2-pyrrolidone,
    • 1-(N-(2,3-Difluorophenyl)-aminocarbonylmethyl)-4(S)-(4-methoxy-3-(3(R)-tetra hydrofuryloxy)phenyl)-2-pyrrolidone,
    • 4(S)-(4-Methoxy-3-(3(R)-tetrahydrofuryloxy)phenyl)-1-(N-(2-methylphenyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4(S)-(4-Methoxy-3-(3(R)-tetrahydrofuryloxy)phenyl)-1-(N-(2-(6-methylpyridinyl))-aminocarbonylmethyl)-2-pyrrolidone, or
  • physiologically acceptable salts thereof, wherein in each case the compound can be in the form of a mixture of enantiomers such as the racemate or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.
  • According to a further preferred compound aspect of the invention, the compound of formula I is selected from:
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-methylbenzyl)-2-pyrrolidone,
    • (4S)-1-(2-chlorobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
    • (4S)-1-(4-Chlorobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
    • (4S)-1-(3-Chlorobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3-methoxybenzyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-fluorobenzyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3-fluorobenzyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(4-fluorobenzyl)-2-pyrrolidone,
    • (4S)-1-(4-Cyanobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-trifluoromethylbenzyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3-trifluoromethylbenzyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(4-trifluoromethylbenzyl)-2-pyrrolidone,
    • (4S)-1-(3,5-bistrifluoromethylbenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3,4-difluorobenzyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3,5-difluorobenzyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2,4-difluorobenzyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2,6-difluorobenzyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2,3-difluorobenzyl)-2-pyrrolidone,
    • (4S)-1-(2-Chloro-4-fluorobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3,4-dichlorobenzyl)-2-pyrrolidone,
    • (4S)-1-(4-tert-Butylbenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-ethyl-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-propyl-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-butyl-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-methoxyethyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-phenylbenzyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-methylbenzyl)-2-pyrrolidone,
    • (4S)-1-(2-Chlorobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
    • (4R)-1-(4-Chlorobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
    • (4R)-1-(3-Chlorobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3-methoxybenzyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-fluorobenzyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3-fluorobenzyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(4-fluorobenzyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-trifluoromethylbenzyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3-trifluoromethylbenzyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(4-trifluorobenzyl)-2-pyrrolidone,
    • (4R)-1-(3,5-bistrifluoromethylbenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3,4-difluorobenzyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3,5-difluorobenzyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2,4-difluorobenzyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2,6-difluorobenzyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2,3-difluorobenzyl)-2-pyrrolidone,
    • (4R)-1-(2-Chloro-4-fluorobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3,4-dichlorobenzyl)-2-pyrrolidone,
    • (4R)-1-(4-tert-Butylbenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-ethyl-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-propyl-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-butyl-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-methoxyphenyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-phenylbenzyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2,6-dimethylphenyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2,6-dimethylphenyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2-methylphenyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2-methylphenyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2-methylphenyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2,3-difluorophenyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(3-chlorophenyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(4-pyridyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(4-methoxyphenyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(4-chloro-2-fluorophenyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(3-methylphenyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(4-methylphenyl)-amino carbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(4-nitrophenyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-1-(N-(2,3-difluorophenyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4(S)-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-1-(N-(2-(6-methylpyridyl))-aminocarbonylmethyl)-2-pyrrolidone,
    • 4(S)-(4-Methoxy-3-(3(R)-tetrahydrofuryloxy)phenyl)-1-(N-(2-(6-methylpyridyl))-aminocarbonylmethyl)-2-pyrrolidone,
    • 1-(N-(2,3-Difluorophenyl)-aminocarbonylmethyl)-4(S)-(4-methoxy-3-(3(R)-tetrahydrofuryloxy)phenyl)-2-pyrrolidone,
    • 1-(N-(2-(6-Aminopyridyl))-aminocarbonylmethyl)-4(S)-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
    • 4(S)-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2-(6-ethylpyridyl))-aminocarbonylmethyl)-2-pyrrolidone,
    • 4(S)-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2-(4,6-dimethylpyridyl))-aminocarbonylmethyl)-2-pyrrolidone,
    • 1-(N-(2-(6-Bromopyridyl))-aminocarbonylmethyl)-4(S)-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
    • 1-(N-(2-(6-Bromopyridyl))-aminocarbonylmethyl)-4(S)-(4-methoxy-3-(3(R)-tetrahydrofuryloxy)phenyl)-2-pyrrolidone,
    • 4(S)-(4-Methoxy-3-(3(R)-tetrahydrofuryloxy)phenyl)-1-(N-(2-methylphenyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4(S)-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(3-(2-methoxypyridyl))-aminocarbonylmethyl)-2-pyrrolidone,
    • 1-(N-(6-(3-Bromo-2-methylpyridyl))-aminocarbonylmethyl)-4(S)-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
    • 4(S)-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(3-(4-methoxycarbonyl)-pyridyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4(S)-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2-(6-methylpyridyl))-aminocarbonylmethyl)-2-pyrrolidone,
    • 1-(N-(3-(2-Cyanopyridyl))-aminocarbonylmethyl)-4(S)-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone, or
    • 4(S)-(4-Methoxy-3-(3(R)-tetrahydrofuryloxy)phenyl)-1-(N-(2-(6-methylpyridinyl))-aminocarbonylmethyl)-2-pyrrolidone, or
  • physiologically acceptable salts thereof, wherein in each case the compound can be in the form of a mixture of enantiomers such as the racemate, or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.
  • Accordingly to a preferred method aspect of the invention, the compound of formula I is selected from:
    • 4-[4-Methoxy-3(4-methoxyphenoxy)phenyl]-2-pyrrolidone,
    • 4-[4-Methoxy-3-(3-thienyloxy)phenyl]-2-pyrrolidone,
    • 4-[3-(4-Fluorophenoxy)-4-methoxyphenyl]-2-pyrrolidone,
    • 4-(3-(3-Cyclohexyl-1-propyloxy)-4-methoxyphenyl)-2-pyrrolidone,
    • 4-(4-Methoxy-3-(2-phenylethoxy)phenyl)-2-pyrrolidone,
    • 4-(4-Methoxy-3-(3-phenyl-1-propoxy)phenyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-chloro-4-fluorobenzyl)-2-pyrrolidone,
    • Methyl 4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone-1-acetate,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-cyanomethyl-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-cyclopentyl-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl) 1-(4-methoxybenzoyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-methylbenzyl)-2-pyrrolidone,
    • (4S)-1-(2-Chlorobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
    • (4S)-1-(4-Chlorobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
    • (4S)-1-(3-Chlorobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3-methoxybenzyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-nitrobenzyl)-2-pyrrolidone,
    • (4S)-4-Cyclopentyloxy-4-methoxyphenyl)-1-(3-nitrobenzyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-fluorobenzyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3-fluorobenzyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(4-fluorobenzyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-benzyl-2-pyrrolidone,
    • (4S)-1-(4-Cyanobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-trifluoromethylbenzyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3-trifluoromethylbenzyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-trifluoromethylbenzyl)-2-pyrrolidone,
    • (4S)-1-(3,5-bistrifluoromethylbenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3,4-difluorobenzyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3,5-difluorobenzyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2,4-difluorobenzyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2,6-difluorobenzyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2,3-difluorobenzyl)-2-pyrrolidone,
  • (4S)-1-(2-Chloro-4-fluorobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3,4-dichlorobenzyl)-2-pyrrolidone,
    • (4S)-1-(4-tert-Butylbenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-ethyl-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-propyl-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-butyl-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-methoxy ethyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-phenylbenzyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-methylbenzyl)-2-pyrrolidone,
    • (4R)-1-(2-Chlorobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
    • (4R)-1-(4-Chlorobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
    • (4R)-1-(3-Chlorobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3-methoxybenzyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-nitrobenzyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3-nitrobenzyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-fluorobenzyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3-fluorobenzyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1′-(4-fluorobenzyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-benzyl-2-pyrrolidone,
    • (4R)-1-(4-Cyanobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-trifluoromethylbenzyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3-trifluoromethylbenzyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(4-trifluoromethylbenzyl)-2-pyrrolidone,
    • (4R)-1-(3,5-bistrifluoromethylbenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3,4-difluorobenzyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3,5-difluorobenzyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2,4-difluorobenzyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2,6-difluorobenzyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2,3-difluorobenzyl)-2-pyrrolidone,
    • (4R)-1-(2-Chloro-4-fluorobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3,4-dichlorobenzyl)-2-pyrrolidone,
    • (4R)-1-(4-tert-Butylbenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-ethyl-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-propyl-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-butyl-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-methoxyethyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-phenylbenzyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2,6-dimethylphenyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2,6-dimethylphenyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2-methylphenyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2-methylphenyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2-methylphenyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2,3-difluorophenyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(3-chlorophenyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(4-pyridyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(4-methoxyphenyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(4-chloro-2-fluorophenyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(3-methylphenyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(4-methylphenyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(4-nitrophenyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(R)-[4-Methoxy-3-(3-(R)-tetrahydrofuryloxy)phenyl]-2-pyrrolidone,
    • 4-(S)-[4-Methoxy-3-(3-(R)-tetrahydrofuryloxy)phenyl]-2-pyrrolidone,
    • 4-(R)-[4-Methoxy-3-(3-(S)-tetrahydrofuryloxy)phenyl]-2-pyrrolidone,
    • 4-(S)-[4-Methoxy-3-(3-(S)-tetrahydrofuryloxy)phenyl]-2-pyrrolidone,
    • 4-[4-Difluoromethoxy-3-(3-(R)-tetrahydrofuryloxy)phenyl]-2-pyrrolidone,
    • 4-[4-Difluoromethoxy-3-(2-cyclohexylethoxy)phenyl]-2-pyrrolidone,
    • 4-[4-Difluoromethoxy-3-(2-phenylethoxy)phenyl]-2-pyrrolidone,
    • 4-[4-Difluoromethoxy-3-(cyclopropylmethoxy)phenyl]-2-pyrrolidone,
    • 4-[4-Difluoromethoxy-3-cyclopentoxyphenyl]-2-pyrrolidone,
    • 4-[4 Difluoromethoxy-3-cyclobutylmethoxyphenyl]-2-pyrrolidone
    • (4R)-1-(2,3-Difluorobenzyl)-4-(3-(3-(S)-tetrahydrofuryl)oxy-4-methoxyphenyl)-2-pyrrolidone,
    • (4S)-1-(2,3-Difluorobenzyl)-4-(3-(3-(S)-tetrahydrofuryl)oxy-4-methoxyphenyl)-2-pyrrolidone,
    • (4R)-1-(2,3-Difluorobenzyl)-4-(3-(3-(R)-tetrahydrofuryl)oxy-4-methoxyphenyl)-2-pyrrolidone,
    • (4S)-1-(2,3-Difluorobenzyl)-4-(3-(3-(R)-tetrahydrofuryl)oxy-4-methoxyphenyl)-2-pyrrolidone,
    • (4S)-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2,3-difluorophenyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • (4R)-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2,3-difluorophenyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-4-(N-(3-(2-chloropyridinyl))-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2-(2-pyridylethyl)) aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2-(2-(N-methylpyrrolidinyl)ethyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(4-pyridylmethyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(1-imidazoylpropyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(4-(4-methylpiperazinyl))-hydrazinocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2-(N-methylpyrrolidinyl)methyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(4-pyrimidinyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1 (N-(3-(5-methylisoxazolyl))-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl) 1-(N-(2,6-dimethylpiperazinyl)-hydrazinocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2-(4,5-dimethylthiazolyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2-(2-methylpiperidinylethyl))-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(3,4-dimethoxyphenethyl))-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2-pyridinyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(3-pyridinyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(3-(2,4-dimethoxypyridinyl))-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(3-(4-methoxypyridinyl))-aminocarbonylmethyl)-2-pyrrolidone,
    • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(4-aniline)-aminocarbonylmethyl)-2-pyrrolidone, 4-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-1-(N-(2,3-difluorophenyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4(S)-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-1-(N-(2-(6-methylpyridyl))-aminocarbonylmethyl)-2-pyrrolidone,
    • 4(S)-(4-Methoxy-3-(3(R)-tetrahydrofuryloxy)phenyl)-1-(N-(2-(6-methylpyridyl))-aminocarbonylmethyl)-2-pyrrolidone,
    • 1-(N-(2,3-Difluorophenyl)-aminocarbonylmethyl)-4(S)-(4-methoxy-3-(3(R)-tetrahydrofuryloxy)phenyl)-2-pyrrolidone,
    • 1-(N-(2-(6-Aminopyridyl))-aminocarbonylmethyl)-4(S)-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
    • 4(S)-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2-(6-ethylpyridyl))-aminocarbonylmethyl)-2-pyrrolidone,
    • 4(S)-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2-(4,6-dimethylpyridyl))-aminocarbonylmethyl)-2-pyrrolidone,
    • 1-(N<2-(6-Bromopyridyl))-aminocarbonylmethyl)-4(S)-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
    • 1-(N-(2-(6-Bromopyridyl))-aminocarbonylmethyl)-4(S)-(4-methoxy-3-(3(R)-tetrahydrofuryloxy)phenyl)-2-pyrrolidone,
    • 4(S)-(4-Methoxy-3(3(R)-tetrahydrofuryloxy)phenyl)-1-(N-(2-methylphenyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4(S)-(3-Cyclopentyloxy-4-methoxyphenyl)-4-(N-(3-(2-methoxypyridyl))-aminocarbonylmethyl)-2-pyrrolidone,
    • 1-(N-(6-(3-Bromo-2-methylpyridyl))-aminocarbonylmethyl)-4(S)-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
    • 4(S)-(3-Cyclopentyloxy-4-methoxyphenyl)-4-(N-(3-(4-methoxycarbonyl)-pyridyl)-aminocarbonylmethyl)-2-pyrrolidone,
    • 4(S)(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2-(6-methylpyridyl))-aminocarbonylmethyl)-2-pyrrolidone,
    • 1-(N-(3-(2-Cyanopyridyl))-aminocarbonylmethyl)-4(S)-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone, or
    • 4(S)-(4-Methoxy-3-(3(R)-tetrahydrofuryloxy)phenyl)-4-(N-(2-(6-methylpyridinyl))-aminocarbonylmethyl)-2-pyrrolidone, or
  • physiologically acceptable salts thereof, wherein in each case the compound can be in the form of a mixture of enantiomers such as the racemate, or a mixture of diastereomers; or can be in the form of a single enantiomer or a single diastereomer.
  • Preferred aspects include pharmaceutical compositions comprising a compound of this invention and a pharmaceutically acceptable carrier and, optionally, another active agent as discussed below; a method of inhibiting a PDE4 enzyme, especially an isoenzyme, e.g., as determined by a conventional assay or one described herein, either in vitro or in vivo (in an animal, e.g., in an animal model, or hi a mammal or in a human); a method of treating a neurological syndrome, e.g., loss of memory, especially long-term memory, cognitive impairment or decline, memory impairment, etc.; a method of treating a disease state modulated by PDE4 activity, in a mammal, e.g., a human, e.g., those disease states mentioned herein.
  • The compounds of the present invention may be prepared conventionally, Some of the known processes that can be used are described below. All starting materials are known or can be conventionally prepared from known starting materials.
    • Preparation of Starting Material (Scheme I)
  • Figure US20090176799A1-20090709-C00005
  • Enantiomerically pure rolipram, 4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone, and the starting material 4-(3-benzyloxy-4-methoxyphenyl)-2-pyrrolidone were prepared as shown in scheme I and in a similar fashion as described previously (J. Demnitz, et al., Enantiodivergent synthesis of (R)- and (S)-Rolipram, Molecules, 1998, 3, 107-119). Thus, appropriately substituted benzaldehydes were condensed with monomethyl
  • Figure US20090176799A1-20090709-C00006
  • malonate to provide the corresponding methyl cinnamyl esters after decarboxylation. Conjugate addition of nitromethane using tetramethyl guanidine as base provided methyl 4-nitro-3-(substituted-phenyl)butyrate. Racemic 4-(3-benzyloxy-4-methoxyphenyl)-2-pyrrolidone was produced in 85% yield by selective reduction of the nitro group to the corresponding amine using NiCl2 and NaBH4 (Osby, J. O.; Ganem, B., Rapid and efficient reduction of aliphatic nitro compounds to amines, Tetrahedron Lett., 1985, 26, 6413-6416) and subsequent treatment with K2CO3.
  • Methyl 4-nitro-3-(substituted-phenyl)butyrate was enantiomerically resolved by synthesizing diastereomeric phenethylamine amides as shown in scheme I. Nitro group reduction by catalytic hydrogenation as described by Demnitz, J. Molecules, 1998, 3, 107-119 was not successful. However, reduction of the diastereomerically pure nitro amides using NiCl2 and NaBH4 produced 90% yield of the corresponding diastereomerically pure amines. Cyclization by warming to reflux in xylene yielded 51% of (S)-(+)-rolipram and 24% of (R)-(−)-rolipram, both in better than 99% ee as determined by chiral HPLC (Kusters, E.; Spondlin, C; Influence of temperature on the enantioseparation of rolipram and structurally related racemates on Chiralcel-OD, J. Chromatography A, 1996, 737, 333-337). Enantiomerically pure 3-benzyloxy derivatives 8 (R-benzyl) were produced in similar yield and purity after cyclization.
  • 3-Aryloxy rolipram derivatives were prepared by cross coupling reaction with aryl boronic acids using a copper catalyst in the presence of an amine base. Suitable copper catalysts include copper diacetate, copper (H) chloride, etc. Generally, halogenated solvents are utilized such as chloroform, dichloromethane, 1,2-dichloroethane, and the like. Commonly used bases include triethylamine, diisopropylamine, and pyrrolidine. Alternatively, 3-phenyloxyrolipram can be prepared by Ullman type coupling starting with iodobenzene and 3-hydroxyrolipram as described previously (Schmiechen, R.; Horowski, R.; Palenschat, D.; Paschelke, G.; Wachtel, H.; Kehr, W., 4-(polyalkoxyphenyl)-2-pyrrolidones, U.S. Pat. No. 4,193,926, filed Mar. 18, 1980). Compounds substituted at the 3-position with arylalkyl, alkyl, cycloalkyl, heteroalkyl or cycloalkylalkyl groups can be prepared by either Mitsunobu reaction between phenol 9 (R1═H) and alcohol or by an alkylation reaction between phenol 9 (R1═H) and R1X, where X is a suitable leaving group such as Cl, Br, methanesulphonyl, tosyloxy, etc.
  • Figure US20090176799A1-20090709-C00007
  • A series of enantiomerically pure N-substituted rolipram derivatives were synthesized by methods common to the art (Christensen, S. B., et. al, 1,4-Cyclohexanecarboxylates: Potent and selective inhibitors of Phosophodiesterase 4 for the treatment of asthma, J. Med. Chem., 1998, 41, 821-835.). Thus, the target compounds
  • Figure US20090176799A1-20090709-C00008
  • can be provided by alkylation reaction with alkyl halides, cycloalkyl halides, arylacyl chlorides, alpha bromoacetates, appropriately substituted alpha-bromides, and arylalkyl halides (i.e., benzylbromides) in polar aprotic solvents (i.e., DMF, THF, DMSO) using a non-nucleophilic base such as NaH or LDA, and a phase transfer catalyst such as 15-crown-5 ether.
  • Reaction of methyl alpha-bromoacetate with a rolipram derivative as described above produces methyl N-acetates 12 (R═CH3), which can be saponified to the acid 12 (R═H) by treatment with a base, such as NaOH or KOH, and then converted to the acid chloride 13 by any number of reagents, such as thionyl chloride or oxalyl chloride. Such acid chlorides undergo reaction with a number of nucleophiles including anilines to provide compounds of type 14.
  • Alternatively, the acid 12 (R═H) undergoes coupling reactions with amines and a suitable coupling reagent such as DCC or HBTU in the presence of an aprotic solvent such as dichloromethane or THF to produce amides of the type 14. In certain instances where R5 is a protecting group such as benzyl this group can be selectively removed from 14 to give the corresponding (R1═H). This phenol can then be substituted by common methods in the art such as by reaction with cyclopentyl bromide in the presence of a suitable base or by a Mitsunobu reaction with 3(S)-hydroxy-tetrahydrofuran to generate desired target compounds.
  • Figure US20090176799A1-20090709-C00009
  • One of ordinary skill in the art will recognize that some of the compounds of Formula (I) can exist in different geometrical isomeric forms. In addition, some of the compounds of the present invention possess one or more asymmetric carbon atoms and are thus capable of existing in the form of optical isomers, as well as in the form of racemic or nonracemic mixtures thereof, and in the form of diastereomers and diastereomeric mixtures inter alia. For example, in the pyrrolidone structure, the carbon atom at the 4-ring position will be chiral. All of these compounds, including cis isomers, trans isomers, diastereomic mixtures, racemates, nonracemic mixtures of enantiomers, substantially pure, and pure enantiomers, are within the scope of the present invention. Substantially pure enantiomers contain no more than 5% w/w of the corresponding opposite enantiomer, preferably no more than 2%, most preferably no more than 1%.
  • In the compounds of formula I, when R3 is H, the 4(R) enantiomers are preferred, and when R3 is other than H, the 4(S)-enantiomers are preferred. When R1 is 3-tetrahydrofuran the 3(R) enantiomers are preferred over the 3(S) enantiomers.
  • The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, for example, by the formation of diastereoisomeric salts using an optically active acid or base or formation of covalent diastereomers. Examples of appropriate acids are tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric and camphorsulfonic acid. Mixtures of diastereoisomers can be separated into their individual diastereomers on the basis of their physical and/or chemical differences by methods known to those skilled in the art, for example, by chromatography or fractional crystallization. The optically active bases or acids are then liberated from the separated diastereomeric salts. A different process for separation of optical isomers involves the use of chiral chromatography (e.g., chiral HPLC columns), with or without conventional derivation, optimally chosen to maximize the separation of the enantiomers. Suitable chiral HPLC columns are manufactured by Diacel, e.g., Chiracel OD and Chiracel OJ among many others, all routinely selectable. Enzymatic separations, with or without derivitization, are also useful. The optically active compounds of Formula I can likewise be obtained by utilizing optically active starting materials in chiral syntheses processes under reaction conditions which do not cause racemization.
  • In addition, one of ordinary skill in the art will recognize that the compounds can be used in different enriched isotopic forms, e.g., enriched in the content of 2H, 3H, 11C, 13C and/or 14C. In one particular embodiment, the compounds are deuterated. Such deuterated forms can be made the procedure described in U.S. Pat. Nos. 5,846,514 and 6,334,997. As described in U.S. Pat. Nos. 5,846,514 and 6,334,997, deuteration can improve the efficacy and increase the duration of action of drugs.
  • Deuterium substituted compounds can be synthesized using various methods such as described in: Dean, Dennis C; Editor. Recent Advances in the Synthesis and Applications of Radiolabeled Compounds for Drug Discovery and Development, [In: Curr., Pharm. Des., 2000; 6(10)] (2000), 110 pp. CAN 133:68895 AN 2000:473538 CAPLUS; Kabalka, George W.; Varma, Rajender S. The synthesis of radiolabeled compounds VIA organometallic intermediates. Tetrahedron (1989), 45(21), 6601-21, CODEN: TETRAB ISSN:0040-4020. CAN 112:20527 AN 1990:20527 CAPLUS; and Evans, E. Anthony. Synthesis of radiolabeled compounds, J. Radioanal. Chem. (1981), 64(1-2), 9-32. CODEN: JRACBN ISSN:0022-4081, CAN 95:76229 AN 1981:476229 CAPLUS.
  • The present invention also relates to useful forms of the compounds as disclosed herein, such as pharmaceutically acceptable salts or prodrugs of all the compounds of the present invention for which salts or prodrugs can be prepared. Pharmaceutically acceptable salts include, those obtained by reacting the main compound, functioning as a base, with an inorganic or organic acid to form a salt, for example, salts of hydrochloric acid, sulfuric acid, phosphoric acid, methane sulfonic acid, camphor sulfonic acid, oxalic acid, maleic acid, succinic acid and citric acid. Pharmaceutically acceptable salts also include those in which the main compound functions as an acid and is reacted with an appropriate base to form, e.g., sodium, potassium, calcium, magnesium, ammonium, and choline salts. Those skilled in the art win further recognize that acid addition salts of the claimed compounds may be prepared by reaction of the compounds with the appropriate inorganic or organic acid via any of a number of known methods. Alternatively, alkali and alkaline earth metal salts are prepared by reacting the compounds of the invention with the appropriate base via a variety of known methods.
  • The following are further examples of acid salts that can be obtained by reaction with inorganic or organic acids: acetates, adipates, alginates, citrates, aspartates, benzoates, benzenesulfonates, bisulfates, butyrates, camphorates, digluconates, cyclopentanepropionates, dodecylsulfates, ethanesulfonates, glucoheptanoates, glycerophosphates, hemisulfates, heptanoates, hexanoates, fumarates, hydrobromides, hydroiodides, 2-hydroxy-ethanesulfonates, lactates, maleates, methanesulfonates, nicotinates, 2-naphthalenesulfonates, oxalates, palmoates, pectinates, persulfates, 3-phenylpropionates, picrates, pivalates, propionates, succinates, tartrates, thiocyanates, tosylates, mesylates and undecanoates.
  • Preferably, the salts formed are pharmaceutically acceptable for administration to mammals. However, pharmaceutically unacceptable salts of the compounds are suitable as intermediates, for example, for isolating the compound as a salt and then converting the salt back to the free base compound by treatment with an alkaline reagent. The free base can then, if desired, be converted to a pharmaceutically acceptable acid addition salt.
  • The compounds of the invention can be administered alone or as an active ingredient of a formulation. Thus, the present invention also includes pharmaceutical compositions of compounds of Formula I, containing, for example, one or more pharmaceutically acceptable carriers.
  • Numerous standard references are available that describe procedures for preparing various formulations suitable for administering the compounds according to the invention. Examples of potential formulations and preparations are contained, for example, in the Handbook of Pharmaceutical Excipients, American Pharmaceutical Association (current edition); Pharmaceutical Dosage Forms: Tablets (Lieberman, Lachman and Schwartz, editors) current edition, published by Marcel Dekker, Inc., as well as Remington's Pharmaceutical Sciences (Arthur Osol, editor), 1553-1593 (current edition).
  • In view of their high degree of selective PDE4 inhibition, the compounds of the present invention can be administered to anyone requiring PDE4 inhibition. Administration may be accomplished according to patient needs, for example, orally, nasally, parenterally (subcutaneously, intravenously, intramuscularly, intrasternally and by infusion) by inhalation, rectally, vaginally, topically and by ocular administration.
  • Various solid oral dosage forms can be used for administering compounds of the invention including such solid forms as tablets, gelcaps, capsules, caplets, granules, lozenges and bulk powders. The compounds of the present invention can be administered alone or combined with various pharmaceutically acceptable carriers, diluents (such as sucrose, mannitol, lactose, starches) and excipients known in the art, including but not limited to suspending agents, solubilizers; buffering agents, binders, disintegrants, preservatives, colorants, flavorants, lubricants and the like. Time release capsules, tablets and gels are also advantageous in administering the compounds of the present invention.
  • Various liquid oral dosage forms can also be used for administering compounds of the inventions, including aqueous and non-aqueous solutions, emulsions, suspensions, syrups, and elixirs. Such dosage forms can also contain suitable inert diluents known in the art such as water and suitable excipients known in the art such as preservatives, wetting agents, sweeteners, flavorants, as well as agents for emulsifying and/or suspending the compounds of the invention. The compounds of the present invention may be injected, for example, intravenously, in the form of an isotonic sterile solution. Other preparations are also possible.
  • Suppositories for rectal administration of the compounds of the present invention can be prepared by mixing the compound with a suitable excipient such as cocoa butter, salicylates and polyethylene glycols. Formulations for vaginal administration can be in the form of a pessary, tampon, cream, gel, paste, foam, or spray formula containing, in addition to the active ingredient, such suitable carriers as are known in the art.
  • For topical administration the pharmaceutical composition can be in the form of creams, ointments, liniments, lotions, emulsions, suspensions, gels, solutions, pastes, powders, sprays, and drops suitable for administration to the skin, eye, ear or nose. Topical administration may also involve transdermal administration via means such as transdermal patches.
  • Aerosol formulations suitable for administering via inhalation also can be made. For example, for treatment of disorders of the respiratory tract, the compounds according to the invention can be administered by inhalation in the form of a powder (e.g., micronized) or in the form of atomized solutions or suspensions. The aerosol formulation can be placed into a pressurized acceptable propellant.
  • The compounds can be administered as the sole active agent or in combination with other pharmaceutical agents such as other agents used in the treatment of cognitive impairment and/or in the treatment of psychosis, e.g., other PDE4 inhibitors, calcium channel blockers, cholinergic drugs, adenosine receptor modulators, amphakines NMDA-R modulators, mGluR modulators, and cholinesterase inhibitors (e.g., donepezil, rivastigimine, and glanthanamine). In such combinations, each active Ingredient can be administered either in accordance with their usual dosage range or a dose below their usual dosage range.
  • The present invention further includes methods of treatment that involve
  • inhibition of PDE4 enzymes. Thus, the present invention includes methods of selective inhibition of PDE4 enzymes in animals, e.g., mammals, especially humans, wherein such inhibition has a therapeutic effect, such as where such inhibition may relieve conditions involving neurological syndromes, such as the loss of memory, especially long-term memory. Such methods comprise administering to an animal in need thereof, especially a mammal, most especially a human, an inhibitory amount of a compound, alone or as part of a formulation, as disclosed herein.
  • The condition of memory impairment is manifested by impairment of the ability to learn new information and/or the inability to recall previously learned information. Memory impairment is a primary symptom of dementia and can also be a symptom associated with such diseases as Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeld-Jakob disease, HIV, cardiovascular disease, and head trauma as well as age-related cognitive decline.
  • Dementias are diseases that include memory loss and additional intellectual impairment separate from memory. The present invention includes methods for treating patients suffering from memory impairment in all forms of dementia. Dementias are classified according to their cause and include: neurodegenerative dementias (Alzheimer's, Parkinson's disease, Pick's disease), vascular (Infarcts, Hemorrhage, Cardiac Disorders), mixed vascular and Alzheimer's, bacterial meningitis, Creutzfeld-Jacob Disease, and multiple sclerosis), traumatic (subdural hematoma or traumatic brain injury), infectious (HIV), toxic (heavy metals, alcohol, medications), metabolic (Vitamin B12 or folate deficiency), CNS hypoxia, Cushing's disease, psychiatric (depression and schizophrenia) and hydrocephalus.
  • The present invention also includes methods for treating memory loss separate from dementias, including mild cognitive impairment (MCI) and age-related cognitive decline. The present invention includes methods of treatment for memory impairment as a result of disease including Huntington's disease and Down's syndrome. According to another aspect, the invention includes methods for treating memory loss from anesthetics, chemotherapy, radiation treatment, and post-surgical trauma.
  • The compounds of the invention can also be used to treat schizophrenia, bipolar or manic depression, major depression, and drug addiction. PDE4 inhibitors can be used to raise cAMP levels and prevent neurons from undergoing apoptosis. PDE4 inhibitors are also known to be anti-inflammatory. The combination of preventing neuronal apoptosis and inhibiting inflammatory responses make these compounds useful to treat neurodegeneration resulting from any disease or injury, including stroke, Alzheimer's disease, multiple sclerosis, amyolaterosclerosis (ALS), and multiple systems atrophy (MSA).
  • Thus, in accordance with a preferred embodiment, the present invention includes methods of treating patients suffering from memory impairment due to, for example, mild cognitive impairment due to aging, Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeld-Jakob disease, depression, aging, head trauma, stroke, CNS hypoxia, cerebral senility, multiinfarct dementia and other neurological conditions, as well as HIV and cardiovascular diseases, comprising administering an effective amount of a compound according to formula (I) or a pharmaceutically acceptable salt thereof.
  • As mentioned, the compounds of the invention also exhibit anti-inflammatory activity. As a result, the inventive compounds are useful in the treatment of a variety of allergic and inflammatory diseases, particularly disease states characterized by decreased cyclic AMP levels and/or elevated phosphodiesterase 4 levels. Thus, in accordance with a further embodiment of the invention, there is provided a method of treating allergic and inflammatory disease states, comprising administering an effective amount of a compound according to formula (I) or a pharmaceutically acceptable salt thereof. Such disease states include; asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD), atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, esoniophilic granuloma, psoriasis, inflammatory arthritis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, chronic glomerulonephritis, endotoxic shock, adult respiratory distress syndrome, cystic fibrosis, arterial restenosis, artherosclerosis, keratosis, rheumatoid spondylitis, osteoarthritis, pyresis, diabetes mellitus, pneumoconiosis, chronic obstructive airways disease, chronic obstructive pulmonary disease, toxic and allergic contact eczema, atopic eczema, seborrheic eczema, lichen simplex, sunburn, pruritis in the anogenital area, alopecia areata, hypertrophic scars, discoid lupus erythematosus, follicular and wide-area pyodermias, endogenous and exogenous acne, acne rosacea, Beghet's disease, anaphylactoid purpura nephritis, inflammatory bowel disease, leukemia, multiple sclerosis, gastrointestinal diseases, autoimmune diseases, osteoporosis, and the like. The compounds can also be used in a method of treating patients suffering from disease states characterized by decreased NMDA function, such as schizophrenia. The compounds can also be used to treat psychosis characterized by elevated levels of PDE 4, for example, various forms of depression, such as manic depression, major depression, and depression associated with psychiatric and neurological disorders.
  • The use of trisubstituted phenyl derivatives for treating asthma, chronic bronchitis, psoriasis, allergic rhinitis, and other inflammatory diseases, and for inhibiting tumor necrosis factor is known within the art. See, e.g., WO 98/58901, JP11-18957, IP 10-072415, WO 93/25517, WO 94/14742, U.S. Pat. No. 5,814,651, and U.S. Pat. No. 5,935,978. These references describe 1,3,4-trisubstituted phenyl compounds said to exhibit PDE4 inhibition activity. They also describe assays for determining PDE4 inhibition activity, and methods for synthesizing such compounds. The entire disclosures of these documents are hereby incorporated by reference.
  • PDE4 inhibitors may be used to prevent or ameliorate osteoporosis, as an antibiotic, for treatment of cardiovascular disease by mobilizing cholesterol from atherosclerotic lesions, to treat rheumatoid arthritis (RA), for long-term inhibition of mesenchymal-cell proliferation after transplantation, for treatment of urinary obstruction secondary to benign prostatic hyperplasia, for suppression of chemotaxis and reduction of invasion of colon cancer cells, for treatment of B cell chronic lymphocytic leukemia (B-CLL), for inhibition of uterine contractions, to attenuate pulmonary vascular ischemia-reperfusion injury (TRI), for corneal hydration, for inhibition of IL-2R expression and thereby abolishing HIV-1 DNA nuclear import into memory T cells, for augmentation of glucose-induced insulin secretion, in both the prevention and treatment of colitis, and to inhibit mast cell degranulation.
  • The compounds of the present invention can be administered as the sole active agent or in combination with other pharmaceutical agents such as other agents used in the treatment of cognitive impairment and/or in the treatment of psychosis, e.g., other PDE4 inhibitors, calcium channel blockers, cholinergic drugs, adenosine receptor modulators, amphakines NMDA-R modulators, mGluR modulators, and cholinesterase inhibitors (e.g., donepezil, rivastigimine, and glanthanamine). In such combinations, each active ingredient can be administered either in accordance with their usual dosage range or a dose below their usual dosage range.
  • The dosages of the compounds of the present invention depend upon a variety of factors including the particular syndrome to be treated, the severity of the symptoms, the route of administration, the frequency of the dosage interval, the particular compound utilized, the efficacy, toxicology profile, pharmacokinetic profile of the compound, and the presence of any deleterious side-effects, among other considerations.
  • The compounds of the invention are typically administered at dosage levels and in a mammal customary for PDE4 inhibitors such as those known compounds mentioned above. For example, the compounds can be administered, in single or multiple doses, by oral administration at a dosage level of generally 0.001-100 mg/ky/day, for example, 0.01-100 mg/kg/day, preferably 0.1-70 mg/kg/day, especially 0.5-10 mg/kg/day. Unit dosage forms can contain generally 0.01-1000 mg of active compound, for example, 0.1-50 mg of active compound. For intravenous administration, the compounds can be administered, in single or multiple dosages, at a dosage level of, for example, 0.001-50 mg/kg/day, preferably 0.001-10 mg/kg/day, especially 0.01-1 mg/kg/day. Unit dosage forms can contain, for example, 0.1-10 mg of active compound.
  • In carrying out the procedures of the present invention it is of course to be understood that reference to particular buffers, media, reagents, cells, culture conditions and the like are not intended to be limiting, but are to be read so as to include all related materials that one of ordinary skill in the art would recognize as being of interest or value in the particular context in which that discussion is presented. For example, it is often possible to substitute one buffer system or culture medium for another and still achieve similar, if not identical, results. Those of skill in the art will have sufficient knowledge of such systems and methodologies so as to be able, without undue experimentation, to make such substitutions as will optimally serve their purposes in using the methods and procedures disclosed herein.
  • The present invention will now be further described by way of the following non-limiting examples. In applying the disclosure of these examples, it should be kept clearly in mind that other and different embodiments of the methods disclosed according to the present invention will no doubt suggest themselves to those of skill in the relevant art.
  • In the foregoing and in the following examples, all temperatures are set forth uncorrected in degrees Celsius; and, unless otherwise indicated, all parts and percentages are by weight.
  • The entire disclosures of all applications, patents and publications, cited above and below, are hereby incorporated by reference.
    • EXAMPLES Intermediate A 4-(3-Benzyloxy-4-methoxyphenyl)-2-pyrrolidone
  • To a mixture of 8.3 g (34.8 mmol) of NiCl2-6H20 in 750 mL of MeOH was slowly added 14 g (104.5 mmol) of NaBH4. This mixture was stirred for 30 minutes at 0° C. and a solution of 25 g of methyl 3-(3-benzyloxy-4-methoxyphenyl)-4-nitrobutanoate in 500 mL of MeOH was added. Then, 8.3 g (34.8 mmol) of NiCl2-6H2O was added to the reaction mixture, followed by the slow portion-wise addition of 9.2 g (243 mmol) of NaBH4. The mixture stirred at 0° C. for 1 hour and then 150 g of K2CO3 was added in one portion. The mixture was allowed to warm to ambient temperature and stirring continued for 18 hours. The suspension was filtered through a pad of celite, washed with 2×1000 mL of MeOH and concentrated. The residue was taken up in 2000 mL of EtOAc and the organic fraction was successively washed with 200 mL of H2O, 250 mL of brine, dried (Na2SO4) and concentrated to a solid. Trituration with hexanes/EtOAc provided 13 g of the desired product. An additional 2.3 g of product was obtained by extracting the aqueous fractions with EtOAc and combining this with the trituration solvent, concentrating and triturating with EtOAc/hexanes. Total yield was 15.3 g (74% yield). 1H NMR (400 MHz, CDCl3) δ 7.44-7.26 (m, 5H), 6.87-6.70 (m, 3H), 5.75 (bs, 1H), 5.14 (s, 2H), 3.87 (s, 3H), 3.70-3.50 (m, 2H), 3.28 (t, 1H), 2.70-2.63 (m, 1H), 2.42-2.35 (m, 1H).
  • 4-(3-Benzyloxy-4-difluoromethoxyphenyl)-2-pyrrolidone was prepared in a similar manner starting with methyl 3-(3-benzyloxy-4-difluoromethoxyphenyl)-4-nitrobutanoate.
    • Intermediate B 4-(3-Hydroxy-4-methoxyphenyl)-2-pyrrolidone
  • A mixture of 3.5 g (11.6 mmol) 4-(3-Benzyloxy-4-methoxyphenyl)-2-pyrrolidone and 350 mg of 10% Pd/C in 50 mL of MeOH and 10 mL of CH2Cl2 was shaken on a Paar apparatus under 20 psi H2 for 8 hours. The mixture was filtered through celite and concentrated leaving 2.4 g (99% yield) of crude material used as such for Examples 1 through 3. 1H NMR (300 MHz, CDCl3) δ 6.82 (s, 1H), 6.79 (d, J=7.6 Hz, 1H), 6.70 (d, J=7.6 Hz, 1H), 6.50 (s, 1H), 3.87 (s, 3H), 3.77 (t, J=8.4 Hz, 1H), 3.62 (t, J=8.0 Hz, 1H), 3.40 (t, J=8.4 Hz, 1H), 2.71 (dd, J=16.8, 8.8 Hz, 1H), 2.49 (dd, J=16.8, 9.0 Hz, 1H).
  • 4-(4-Difluoromethoxy-3-hydroxyphenyl)-2-pyrrolidone was prepared in a similar fashion starting with 4-(3-benzyloxy-4-difluoromethoxyphenyl)-2-pyrrolidone
    • Example 1 4-(4-Chlorophenoxy-3-methoxyphenyl)-2-pyrrolidone
  • A mixture of 4-(3-hydroxy-4-methoxyphenyl)-2-pyrrolidone (63 mg, 0.3 mmol), 4-chlorophenylboronic acid (61 mg; 0.45 mmol), copper (II) acetate (54 mg, 0.3 mmol), triethylamine (152 mg, 1.5 mmol), dichloromethane (3 ml) and small amount of molecular sieves is allowed to stir at ambient temperature. After 18 hours, the mixture is filtered over celite and the filtrate is concentrated under vacuum. The resulting residue is dissolved in 30 ml of ethyl acetate and washed successively with saturated aqueous sodium bicarbonate solution and brine. Purification by flash column chromatography (ethyl acetate/hexane 1:1 to methanol/dichloromethane 3:97) gives 26 mg (27%) of 4-(3-(4-chlorophenyloxy)-4-methoxyphenyl)-2-pyrrolidone: 1H NMR (300 MHz, CDCl3) δ 7.24 (d, J=9.2 Hz, 2H), 7.03 (d, J=8.4 Hz, 1H), 6.95 (d, J=8.4 Hz, 1H), 6.87 (s, 1H), 6.83 (d, J=9.2 Hz, 2H), 5.83 (b, 1H), 3.80 (s, 3H), 3.72 (t, J=8.4 Hz, 1H), 3.65-3.62 (m, 1H), 3.34 (t, J=8.4 Hz, 1H), 2.68 (dd, J=16.8, 8.8 Hz, 1H), 2.41 (dd, J=16.8, 9.2 Hz, 1H).
  • The following compounds were prepared in a similar fashion starting with different arylboronic acids and aryl vinyl boronic acids:
    • A. 4-(4-Methoxy-3-phenoxyphenyl)-2-pyrrolidone
    • B. 4-[4-Methoxy-3-(4-methoxyphenoxy)phenyl]-2-pyrrolidone
    • C. 4-[4-Methoxy-3-(3-thienyloxy)phenyl]-2-pyrrolidone
    • D. 4-[3-(4-Fluorophenoxy)-4-methoxyphenyl]-2-pyrrolidone
    • E. 4-[3-Cyanophenoxy-4-methoxyphenyl]-2-pyrrolidone
    • F. 4-[4-Methoxy-3-naphthyloxyphenyl]-2-pyrrolidone
    • G. 4-[4-Methoxy-3-((2-phenyl)ethenyloxy)phenyl]-2-pyrrolidone
    • H. 4-[4-Methoxy-3-((2-(4-chlorophenyl)ethenyloxy)phenyl]-2-pyrrolidone
  • The separate enantiomers of racemic compounds listed above can be obtained through the use of optically active starting materials or by conventional resolution techniques such as chiral HPLC.
    • Example 2 4-(3-Cinnamyloxy-4-methoxyphenyl)-2-pyrrolidone
  • Diisopropylazodicarboxylate (63 mg, 0.6 mmol) is added to a solution of 4-(3-hydroxy-4-methoxyphenyl)-2-pyrrolidone (63 mg. 0.36 mmol), cinnamyl alcohol (43 mg, 0.3 mmol) and triphenyl phosphine (157 mg, 0.6 mmol) in 3 ml of tetrahydrofuran and the reaction mixture is stirred at 70° C. After 12 hours, the same work-up procedure as in Example 1 yields 70 mg (70%) of 4-(3-cinnamyloxy-4-methoxyphenyl)-2-pyrrolidone: 1H NMR (300 MHz, CDCl3) δ 7.40 (d, J=6.8 Hz, 2H), 7.31 (t, J=6.8 Hz, 2H), 7.25 (d, J=7:2 Hz, 1H), 6.86-6.81 (m, 2H), 6.71 (d, J=15.6 Hz, 1H), 6.42 (m, 1H), 5.92 (b, 1H), 4.76 (dd, J=6.0, 1.2 Hz, 2H), 3.87 (s, 3H), 3.71 (t, J=8.8 Hz, 1H), 3.64-3.56 (m, 1H), 3.35 (t, J=8.8 Hz, 1H).
  • The following compounds were prepared in a similar fashion starting with different alcohols:
    • A. 4-(3-(3-Cyclohexyl-1-propyloxy)-4-methoxyphenyl)-2-pyrrolidone
    • B. 4-(4-Methoxy-3-(3-phenyl-1-butyloxy)phenyl)-2-pyrrolidone
    • C. 4-[4-Methoxy-3-indanyloxyphenyl]-2-pyrrolidone
    • D. 4-[4-Methoxy-3-(2-(4-chlorophenethyl)ethoxy)phenyl]-2-pyrrolidone
    • E. 4-[4-Methoxy-3-(2-(4-methylphenyl)ethoxy)phenyl]-2-pyrrolidone
    • F. 4-[4-Methoxy-3-(2-(2-thienyl)ethoxy)phenyl]-2-pyrrolidone
    • G. 4-[4-Methoxy-3-(2-(3-chlorophenyl)ethoxy)phenyl]-2-pyrrolidone
    • H. 4-[4-Methoxy-3-(2-(4-fluorophenyl)ethoxy)phenyl]-2-pyrrolidone
    • I. 4-[4-Methoxy-3-(2-(4-pyridyl)ethoxy)phenyl-2-pyrrolidone
    • J. 4-[4-Methoxy-3-(3-(R)-tetrahydrofuryloxy)phenyl]-2-pyrrolidone
    • K. 4-[4-Methoxy-3-(3-(S)-tetrahydrofuryloxy)phenyl]-2-pyrrolidone
    • L. 4-[4-Methoxy-3-(2-(4-cyanophenyl)ethoxy)phenyl]-2-pyrrolidone
    • M. 4-[4-Methoxy-3-(3-(4-chlorophenyl)propoxy)phenyl]-2-pyrrolidone
    • N. 4-[4-Methoxy-3-(2-(3-methylphenyl)ethoxy)phenyl]-2-pyrrolidone
    • O. 4-(R)-[4-Methoxy-3-(3-(R)-tetrahydrofuryloxy)phenyl]-2-pyrrolidone
    • P. 4-(S)-[4-Methoxy-3-(3-(R)-tetrahydrofuryloxy)phenyl]-2-pyrrolidone
    • Q. 4-(R)-[4-Methoxy-3-(3-(S)-tetrahydrofuryloxy)phenyl]-2-pyrrolidone
    • R. 4-(S)-[4-Methoxy-3-(3-(S)-tetrahydrofuryloxy)phenyl]-2-pyrrolidone
    • S. 4-[4-Methoxy-3-cyclopropylmethoxyphenyl]-2-pyrrolidone
    • T. 4-[4-Methoxy-3-cyclobutylmethoxyphenyl]-2-pyrrolidone
    • U. 4-[4-Methoxy-3-cycloheptyloxyphenyl]-2-pyrrolidone
    • V. 4-[4-Methoxy-3-cyclohexylmethoxyphenyl]-2-pyrrolidone
    • W. 4-[4-Methoxy-3-(2-cyclohexyl)ethoxyphenyl]-2-pyrrolidone
    • X. 4-[4-Methoxy-3-cyclopentylmethoxyphenyl]-2-pyrrolidone
    • Y. 4-[4-Methoxy-3-cyclohexyloxyphenyl]-2-pyrrolidone
    • Z. 4-[4-Methoxy-3-(3-cyclopentyl)propoxyphenyl]-2-pyrrolidone
    • AA. 4-[4-Difluoromethoxy-3-(3-(R)-tetrahydro furyloxy)phenyl]-2-pyrrolidone
    • BB. 4-[4-Difluoromethoxy-3-(2-cyclohexylethoxy)phenyl]-2-pyrrolidone
    • CC. 4-[4-Difluoromethoxy-3-(2-phenylethoxy)phenyl]-2-pyrrolidone
    • DD. 4-[4-Difluoromethoxy-3-(cyclopropylmethoxy)phenyl]-2-pyrrolidone
  • The separate enantiomers of racemic compounds listed above can be obtained through the Use of optically active starting materials or by conventional resolution techniques such as chiral HPLC.
    • Example 3 4-(4-Methoxy-3-phenpropyloxyphenyl)-2-pyrrolidone
  • A mixture of 4-(3-hydroxy-4-methoxyphenyl)-2-pyrrolidone (42 mg, 0.2 mmol), 3-phenylpropyl bromide (44 mg, 0.22 mmol), potassium carbonate (83 mg, 0.6 mmol) and N,N-dimethylformamide (3 ml) is allowed to stir at 100° C. After 18 hours, the reaction mixture is cooled to 25° C. The solid is filtered off and the filtrate is concentrated under vacuum. The same working up procedure gives 47 mg (72%) of 4-(3-(3-phenylpropoxy)-4-methoxyphenyl)-2-pyrrolidone: 1H NMR (300 MHz, CDCl3) δ 7.34-7.17 (m, 5H), 6.82 (d, J=8.4 Hz, 1H), 6.78 (d, 12 Hz, 1H), 6.70 (s, 1H), 6.02 (b, 1H), 4.03 (t, J=7.2 Hz, 2H), 3.84 (s, 3H), 3.75 (t, J=8.8 Hz, 1H), 3.63-3.55 (m, 1H), 3.36 (t, J=8.8 Hz, 1H), 2.82 (t, J=8.0 Hz, 2H), 2.71 (dd, J=16.8, 8.8 Hz, 2H), 2.47 (dd, J=16.6, 8.8 Hz), 2.20-2.13 (m, 2H).
  • The following compounds were prepared in a similar fashion starting with different arylalkyl bromides and alkyl bromides:
    • A. 4-(4-Methoxy-3-(2-phenylethoxy)phenyl)-2-pyrrolidone
    • B. 4-(4-Methoxy-3-(3-phenyl-1-propoxy)phenyl)-2-pyrrolidone
    • C. 4-[4-methoxy-3-[1-(3-phenyl-2-propenyl)oxyphenyl]-2-pyrrolidone
    • D. 4-[4-methoxy-3-(2-cyclopropylethoxy)phenyl]-2-pyrrolidone
    • E. 4-[4-methoxy-3-(2-cyclopentylethoxy)phenyl]-2-pyrrolidone
    • F. 4-[4-Difluoromethoxy-3-cyclopentoxyphenyl]-2-pyrrolidone
    • G. 4-[4-Difluoromethoxy-3-cyclobutylmethoxyphenyl]-2-pyrrolidone
  • The separate enantiomers of racemic compounds listed above can be obtained through the use of optically active starting materials or by conventional resolution techniques such as chiral HPLC.
    • Example 4 (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2,3-difluorobenzyl)-2-pyrrolidone
  • 4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (110 mg, 0.4 mmol) in 2 ml of N,N-dimethylformamide and 110 μl of 15-crown-5 is treated with sodium hydride (20 mg, 0.5 mmol) under nitrogen at ambient temperature. After 3 hours, the mixture is cooled to 0° C. and treated with 2,3-difluorobenzyl bromide (166 mg, 0.8 mmol) in 2 ml of tetrahydrofuran. The resulting mixture is allowed to stir at ambient temperature for 6 hours. 100 ml of ethyl acetate is added, followed by 100 ml of ice cold water. After usual aqueous work up, the crude product is purified by flash column chromatography (ethyl acetate/hexane 2:1) to give 112 mg (70%) of 1-(2,3-difluorobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone: 1H NMR (300 MHz, CDCl3) δ 7.18-6.98 (m, 3H), 6.79 (d, J=8.1 Hz, 1H), 6.90 (d, J=8.1 Hz, 1H), 6.68 (s, 1H) 4.71-4.69 (m, 1H), 4.60 (s, 2H), 3.81 (s, 3H), 3.68 (t, J=9.0 Hz, 1H), 3.66-3.54 (m, 1H), 3.29 (dd, J=9.6, 7.2 Hz, 1H), 2.84 (dd, 16.8, 9.0 Hz, 1H), 2.57 (dd, J=16.8, 8.4 Hz, 1H), 2.00-1.75 (b, 6H), 1.70-1.52 (b, 2H).
  • The following compounds were prepared in a similar fashion starting with different 4-(3-Substituted)-oxy-4-methoxyphenyl)-2-pyrrolidone and reacting it with different arylalkyl bromides and alkyl bromides:
    • A. (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-methylbenzyl)-2-pyrrolidone
    • B. (4S)-1-(2-Chlorobenzyl)-4(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone
    • C. (4<S)-1-(4-Chlorobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone
    • D. (4S)-1-(3-Chlorobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone
    • E. (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3-methoxybenzyl)-2-pyrrolidone
    • F. (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-nitrobenzyl)-2-pyrrolidone
    • G. (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3-nitrobenzyl)-2-pyrrolidone
    • H. (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-fluorobenzyl)-2-pyrrolidone
    • I. (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3-fluorobenzyl)-2-pyrrolidone
    • J. (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(4-fluorobenzyl)-2-pyrrolidone
    • K. (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-benzyl-2-pyrrolidone
    • L. (4S)-1-(4-Cyanobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone
    • M. (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-trifluoromethylbenzyl)-2-pyrrolidone
    • N. (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3-trifluoromethylbenzyl)-2-pyrrolidone
    • O. (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(4-trifluoromethylbenzyl)-2-pyrrolidone
    • P. (4S)-(3,5-Bistrifluoromethylbenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone
    • Q. (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3,4-difluorobenzyl)-2-pyrrolidone
    • R. (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3,5-difluorobenzyl)-2-pyrrolidone
    • S, (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2,4-difluorobenzyl)-2-pyrrolidone
    • T. (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2,6-difluorobenzyl)-2-pyrrolidone
    • U. (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2,3-difluorobenzyl)-2-pyrrolidone
    • V. (4S)-1-(2-Chloro-4-fluorobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone
    • W. (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3,4-dichlorobenzyl)-2-pyrrolidone
    • X. (4S)-1-(4-tert-Butylbenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone
    • Y. (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-ethyl-2-pyrrolidone
    • Z. (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-propyl-2-pyrrolidone
    • AA. (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-butyl-2-pyrrolidone
    • BB. (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-methoxyethyl)-2-pyrrolidone
    • CC. (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-phenylbenzyl)-2-pyrrolidone
    • DD. (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-methylbenzyl)-2-pyrrolidone
    • EE. (4R)-1-(2-Chlorobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone
    • FF. (4R)-1-(4-Chlorobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone
    • GG. (4R)-1-(3-Chlorobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone
    • HH. (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3-methoxybenzyl)-2-pyrrolidone
    • II. (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-nitrobenzyl)-2-pyrrolidone
    • JJ. (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3-nitrobenzyl)-2-pyrrolidone
    • KK. (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-fluorobenzyl)-2-pyrrolidone
    • LL. (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3-fluorobenzyl)-2-pyrrolidone
    • MM. (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(4-fluorobenzyl)-2-pyrrolidone
    • NN. (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-benzyl-2-pyrrolidone
    • OO. (4R)-1-(4-Cyanobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone
    • PP. (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-trifluoromethylbenzyl)-2-pyrrolidone
    • QQ. (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3-trifluoromethylbenzyl)-2-pyrrolidone
    • RR. (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(4-trifluoromethylbenzyl)-2-pyrrolidone
    • SS. (4R)-1-(3,5-bistrifluoromethylbenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone
    • TT. (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3,4-difluorobenzyl)-2-pyrrolidone
    • UU. (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3,5-difluorobenzyl)-2-pyrrolidone
    • VV. (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2,4-difluorobenzyl)-2-pyrrolidone
    • WW. (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2,6-difluorobenzyl)-2-pyrrolidone
    • XX. (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2,3-difluorobenzyl)-2-pyrrolidone
    • YY. (4R)-1-(2-Chloro-4-fluorobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone
    • ZZ. (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3,4-dichlorobenzyl)-2-pyrrolidone
    • AAA. (4R)-1-(4-tert-Butylbenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone
    • BBB. (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-ethyl-2-pyrrolidone
    • CCC. (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-propyl-2-pyrrolidone
    • DDD. (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-butyl-2-pyrrolidone
    • EEE. (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-methoxyethyl)-2-pyrrolidone
    • FFF. (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-phenylbenzyl)-2-pyrrolidone
    • GGG. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-chloro-4-fluorobenzyl)-2-pyrrolidone
    • HHH. (4R)-Methyl-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone-1-acetate
    • III. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-cyanomethyl-2-pyrrolidone
    • JJJ. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-cyclopentyl-2-pyrrolidone
    • KKK. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(4-methoxybenzoyl)-2-pyrrolidone
    • LLL. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(4-chlorobenzoyl)-2-pyrrolidone
    • MMM. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(4-nitrobenzoyl)-2-pyrrolidone
    • NNN. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-benzoyl-2-pyrrolidone
    • OOO. (4R)-1-(2,3-Difluorobenzyl)-4-(3-(3-(S)-tetrahydrofuryl)oxy-4-methoxyphenyl)-2-pyrrolidone
    • PPP. (4S)-1-(2,3-Difluorobenzyl)-4-(3-(3-(S)-tetrahydrofuryl)oxy-4-methoxyphenyl)-2-pyrrolidone
    • QQQ. (4R)-1-(2,3-Difluorobenzyl)-4-(3-(3-(R)-tetrahydrofuryl)oxy-4-methoxyphenyl)-2-pyrrolidone
    • RRR. (4S)-1-(2,3-Difluorobenzyl)-4-(3-(3-(R)-tetrahydrofuryl)oxy-4-methoxyphenyl)-2-pyrrolidone
  • The separate enantiomers of racemic compounds listed above can be obtained through the use of optically active starting materials or by conventional resolution techniques such as chiral HPLC.
    • Example 5 Intermediate 4-(3-Cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone-1-acetic acid
  • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone-1-acetate (250 mg, 0.72 mmol) was treated with 8 ml of a 1M solution of potassium hydroxide in 95% methanol. After 10 hours, the reaction solution was acidified with 2N HCl to pH 3 and 30 ml of water was added and the resulting mixture was extracted with 60 ml of ethyl acetate twice, The organic layer was concentrated and chromatographed (methanol/dichloromethane 5:100) to give 242 mg (quantitative yield) of 4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone-1-acetic acid: 1H NMR (300 MHz, CDCl3) δ 6.85-73 (m, 3H), 4.84-4.74 (m, 1H), 4.20 (d, J=12.0 Hz, 1H), 4.12 (d, J=12.0, 1H), 3.82 (s, 4H), 3.66-3.46 (m, 2H), 2.89 (dd, J=16.8, 8.7 Hz, 1H), 2.58 (dd, J=16.8, 8.4 Hz, 1H), 2.00-1.72 (b, 6H), 1.70-1.50 (b, 2H).
    • Example 6 4-(3-Cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone-1-acetyl chloride
  • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone-1-acetic acid (50 mg, 0.15 mmol) was dissolved in 3 mL of CH2Cl2 and treated with oxalylchloride (0.17 mmol) at 4° C. The reaction mixture was stirred at ambient temperature for 2 hours and concentrated in vacuo,
    • Example 7 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2,6-dimethylphenyl)-aminocarbonylmethyl)-2-pyrrolidone
  • 4-(3-Cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone-1-acetyl chloride was taken up in 3 ml of CH2Cl2 and added to a solution of 1,6-dimethylaniline (39 mg, 0.3 mmol) in tetrahydrofuran (2 ml) containing diisopropylethylamine (39 mg, 0.3 mmol). After 3 hours, the mixture is concentrated in vacuo, the residue was dissolved in 50 ml of EtOAc, washed with 50 ml of 1 N HCl, 50 mL of water, and 50 mL of aqueous saturated sodium bicarbonate solution. The organic phase was concentrated and chromatographed over SiO2 to give 49 mg (75% yield) of the target acetamide: 1H NMR (300 MHz, CDCl3) δ 7.68 (s, 1H), 7.18-7.03 (m, 3H), 6.84-6.73 (m, 3H), 4.84-4.70 (m, 1H), 4.16 (d, 11.4 Hz, 1H), 4.13 (d, J=11.4 Hz, 1H), 3.94 (t, J=8.0 Hz, 1H), 3.85-3.75 (m, 4H), 3.68-3.46 (m, 2H), 2.86 (dd, J=16.8, 8.4 Hz, 1H), 2.61 (dd, J=16.8, 8.4 Hz, 1H), 2.19 (s, 6H), 1.98-1.72 (b, 6H), 1.70-1.53 (b, 2H).
  • The following compounds were synthesized in a similar manner as described above;
    • A. (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2,6-dimethylphenyl)-aminocarbonylmethyl)-2-pyrrolidone
    • B. (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2,6-dimethylphenyl)-aminocarbonylmethyl)-2-pyrrolidone
    • C. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2-methylphenyl)-aminocarbonylmethyl)-2-pyrrolidone
    • D. (4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2-methylphenyl)-aminocarbonylmethyl)-2-pyrrolidone
    • E. (4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2-methylphenyl)-aminocarbonylmethyl)-2-pyrrolidone
    • F. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2,3-difluorophenyl)-aminocarbonylmethyl)-2-pyrrolidone
    • G. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(3-chlorophenyl)-aminocarbonylmethyl)-2-pyrrolidone
    • H. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(4-pyridyl)-aminocarbonylmethyl)-2-pyrrolidone
    • I. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(4-methoxyphenyl)-aminocarbonylmethyl)-2-pyrrolidone
    • J. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(4-chloro-2-fluorophenyl)-aminocarbonylmethyl)-2-pyrrolidone
    • K. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(3-methylphenyl)-aminocarbonylmethyl)-2-pyrrolidone
    • L. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(4-methylphenyl)-aminocarbonylmethyl)-2-pyrrolidone
    • M. 4-(3-Cyclopentyloxy-4-methoxyphenyl) 1-(N-(4-nitrophenyl)-aminocarbonylmethyl)-2-pyrrolidone
    • N. (4S)-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2,3-difluorophenyl)-aminocarbonylmethyl)-2-pyrrolidone
    • O. (4R)-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2,3-difluorophenyl)-aminocarbonylmethyl)-2-pyrrolidone
    • P. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(3-(2-chloropyridinyl))-aminocarbonylmethyl)-2-pyrrolidone
    • Q. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2-(2-pyridylethyl))-aminocarbonylmethyl)-2-pyrrolidone
    • R. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2-(2-(N-methylpyrrolidinyl)ethyl))-aminocarbonylmethyl)-2-pyrrolidone
    • S. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(4-pyridylmethyl)-aminocarbonylmethyl)-2-pyrrolidone
    • T. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(1-imidazoylpropyl)-aminocarbonylmethyl)-2-pyrrolidone
    • U. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(4-(4-methylpiperazinyl))-hydrazinocarbonylmethyl)-2-pyrrolidone
    • V. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2-(N-methylpyrrolidinyl)methyl)-aminocarbonylmethyl)-2-pyrrolidone
    • W. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(4-pyrimidinyl)-aminocarbonylmethyl)-2-pyrrolidone
    • X. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(3-(5-methylisoxazolyl))-aminocarbonylmethyl)-2-pyrrolidone
    • Y. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2,6-dimethylpiperazinyl)-hydrazinocarbonylmethyl)-2-pyrrolidone
    • Z. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2-(4,5-dimethylthiazolyl))-aminocarbonylmethyl)-2-pyrrolidone
    • AA. 4-(3 Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2-(2-methylpiperidinyl)ethyl)-aminocarbonylmethyl)-2-pyrrolidone
    • BB. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(3,4-dimethoxyphenethyl)-aminocarbonylmethyl)-2-pyrrolidone
    • CC. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2-pyridinyl)-aminocarbonylmethyl)-2-pyrrolidone
    • DD. 4-(3-Cyclopentyl oxy-4-methoxyphenyl)-1-(N-(3-pyridinyl)-aminocarbonylmethyl)-2-pyrrolidone
    • EE. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(3-(2,4-dimethoxypyridinyl))-aminocarbonylmethyl)-2-pyrrolidone
    • FF. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(3-(4-methoxypyridinyl))-aminocarbonylmethyl)-2-pyrrolidone
    • GG. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(4-tert-butyloxycarbonylaminophenyl)-aminocarbonylmethyl)-2-pyrrolidone
  • The separate enantiomers of racemic compounds listed above can be obtained through the use of optically active starting materials or by conventional resolution techniques such as chiral HPLC.
    • Example 8 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(4-anilino)-aminocarbonylmethyl)-2-pyrrolidone
  • A mixture of 4-(3-cyclopentyloxy-4-methoxyphenyl)-1-(N-(4-tert-butyloxycarbonylaminophenyl)aminocarbonylmethyl)-2-pyrrolidone was stirred in a 1:2 mixture of TFA and dichloromethane for 2 hours at room temperature. The material was concentrated in vacuo and purified by column chromatography over. SiO2 to provide the pure aniline.
    • Example 9 In Vitro Measurement of Type 4 Phosphodiesterase Enzyme Preparation:
  • Human PDE4 was obtained from baculovirus-infected Sf9 cells that expressed the recombinant enzyme. The cDNA encoding hPDE-4D6 was subcloned into a baculovirus vector. Insect cells (Sf9) were infected with the baculovirus and cells were cultured until protein was expressed. The baculovirus-infected cells were lysed and the lysate was used as source of hPDE-4D6 enzyme. The enzyme was partially purified using a DEAE ion exchange chromatography. This procedure can be repeated using cDNA encoding other PDE-4 enzymes.
    • Assay:
  • Type 4 phosphodiesterases convert cyclic adenosine monophosphate (cAMP) to 5′-adenosine monophosphate (5′-AMP). Nucleotidase converts 5′-AMP to adenosine. Therefore the combined activity of PDE4 and nucleotidase converts cAMP to adenosine. Adenosine is readily separated from cAMP by neutral alumina columns. Phosphodiesterase inhibitors block the conversion of cAMP to adenosine in this assay; consequently, PDE4 inhibitors cause a decrease in adenosine,
  • Cell lysates (40 ul) expressing hPDE-4D6 were combined with 50 ul of assay mix and 10 ul of inhibitors and incubated for 12 min at room temperature. Final concentrations of assay components were: 0.4 ug enzyme, 10 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 3 uM cAMP, 0.002 U 5′-nucleotidase, and 3×104 cpm of [3H]cAMP. The reaction was stopped by adding 100 μl of boiling 5 mN HCl. An aliquot of 75 μl of reaction mixture was transferred from each well to alumina columns (Multiplate; Millipore). Labeled adenosine was eluted into an OptiPlate by spinning at 2000 rpm for 2 min; 150 μl per well of scintillation fluid was added to the OptiPlate. The plate was sealed, shaken for about 30 min, and cpm of [3H]adenosine was determined using a Packard Topcount 96 counter.
  • All test compounds are dissolved in 100% DMSO and diluted into the assay such that the final concentration of DMSO is 0.1%. DMSO does not affect enzyme activity at this concentration.
    • Example 10 Passive Avoidance in Rats, an In Vivo Test for Learning and Memory
  • The test was performed as previously described (Zhang, H.-T., Crissman, A. M., Dorairaj, N. R., Chandler, L. J., and O'Donnell, J. M., Neuropsychopharmacology, 2000, 23, 198-204.). The apparatus (Model E10-16SC, Coulbourn Instruments, Allentown, Pa.) consisted of a two-compartment chamber with an illuminated compartment connected to a darkened compartment by a guillotine door. The floor of the darkened compartment consisted of stainless steel rods through which an electric foot-shock could be delivered from a constant current source. All experimental groups were first habituated to the apparatus the day before the start of the experiment During the training, the rat (Male Sprague-Dawley (Harlan) weighing 250 to 350 g) was placed in the illuminated compartment facing away from the closed guillotine door for 1 minute before the door was raised. The latency for entering the darkened compartment was recorded. After the rat entered the darkened compartment, the door was closed and a 0.5 mA electric shock was administered for 3 seconds. Twenty-four hours later, the rat was administered 0.1 mg/kg of the test compound or saline, 30 minutes prior to the injection of saline or test compound (dosed from 0.1 to 2.5 mg/kg, i.p.), which was 30 minutes before the retention test started. The rat was again placed in the illuminated compartment with the guillotine door open. The latency for entering the darkened compartment was recorded for up to 180 seconds, at which time the trial was terminated.
  • All data were analyzed by analyses of variance (ANOVA); individual comparisons were made using Kewman-Keuls tests. Naïve rats required less than 30 seconds, on average, to cross from the illuminated compartment to the darkened compartment.
    • Example 11 Radial Arm Maze Task in Rats, an In Vivo Test for Learning and Memory
  • The test was performed as previously described (Zhang, H.-T., Crissman, A. M., Dorairaj, N. R., Chandler, L. J. and O'Donnell, J. M., Neuropsychopharmacology, 2000, 23, 198-204.). Five days after initial housing, rats (male Sprague-Dawley (Harlan) weighing 250 to 350 g) were placed in the eight-arm radial maze (each arm was 60×10×12 cm high; the maze was elevated 70 cm above the floor) for acclimation for two days. Rats were then placed individually in the center of the maze for 5 minutes with food pellets placed close to the food wells, and then, the next day, in the wells at the end of the arms; 2 sessions a day were conducted. Next, four randomly selected arms were then baited with one pellet of food each. The rat was restricted to the center platform (26 cm in diameter) for 15 seconds and then allowed to move freely throughout the maze until it collected all pellets of food or 10 minutes passed, whichever came first. Four parameters were recorded: 1) working memory errors, i.e., entries into baited arms that had already been visited during the same trial; 2) reference memory errors, i.e., entries into unbaited arms; 3) total arm entries; and 4) the test duration (seconds), i.e., the time spent in the collection of all the pellets in the maze. If the working memory error was zero and the average reference memory error was less than one in five successive trials, the rats began the drug tests. The test compound or saline was injected 15 minutes prior to vehicle or test agent, which was given 45 minutes before the test. Experiments were performed in a lighted room, which contained several extra-maze visual cues.
  • All data were analyzed by analyses of variance (ANOVA); individual comparisons were made using Kewman-Keuls tests.
  • A decrease in adenosine concentration is indicative of inhibition of PDE activity. This procedure was used to screen compounds of the present invention for their ability to inhibit PDE4. pIC50 values were determined by screening 6 to 12 concentrations of compound ranging from 0.1 nM to 10,000 nM and then plotting drug concentration versus 3H-adenosine concentration. Prism® was used to estimate pIC50 values.
  • The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.
  • While the invention has been illustrated with respect to the production and of particular compounds, it is apparent that variations and modifications of the invention can be made without departing from the spirit or scope of the invention.

Claims (22)

1. A compound of Formula I:
Figure US20090176799A1-20090709-C00010
wherein
X is O;
R1 is alkyl having 1 to 8 carbon atoms wherein optionally one or more —CH2CH2— groups are replaced in each case by —CH═CH— or —C═C— groups,
alkyl having 1 to 8 carbon atoms which is substituted one or more times by halogen, oxo or combinations thereof wherein optionally one or more —CH2CH2— groups are replaced in each case by —CH═CH— or —C═C— groups,
cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl having 1 to 4 carbon atoms or combinations thereof,
a heterocyclic group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom which is unsubstituted or substituted one or more times by halogen, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof,
aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF3 OCF3, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido and acyloxy or combinations thereof,
arylalkyl having 8 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF3 OCF3, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido and acyloxy or combinations thereof,
a partially unsaturated carbocyclic group having 5 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, alkyl, alkoxy, nitro, cyano, oxo, or combinations thereof,
arylalkenyl having 8 to 16 carbon atoms, wherein the alkenyl portion has up to 5 carbon atoms, which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido and acyloxy, or combinations thereof;
a heterocyclic-alkyl group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, wherein the heterocyclic portion is unsubstituted or substituted one or more times by halogen, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, dialkylamino, carboxy or combinations thereof and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof, or
cycloalkylalkyl having 4 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl or combinations thereof,
R2 is alkyl having 1 to 4 carbon atoms, which is unsubstituted or substituted one or more times by halogen;
R3 is H,
alkyl having 1 to 8 carbon atoms wherein optionally one or more —CH2CH2— groups are replaced in each case by —CH═CH— or —C≡C— groups,
alkyl having 1 to 8 carbon atoms which is substituted one or more times by halogen, oxo, or combinations thereof wherein optionally one or more —CH2CH2— groups are replaced in each case by —CH═CH— or —C≡C— groups,
cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl, or combinations thereof,
arylalkyl having 7 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, and acyloxy or combinations thereof,
a heterocyclic-alkyl group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, wherein the heterocyclic portion is unsubstituted or substituted one or more times by halogen, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, dialkylamino, carboxy or combinations thereof and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof,
alkoxyalkyl having 3 to 8 carbon atoms,
—C(O)R4, or
—CH2CONHR5;
R4 is alkyl having 1 to 12 carbon atoms wherein optionally one or more —CH2CH2— groups are replaced in each case by —CH═CH— or —C≡C— groups,
alkyl having 1 to 12 carbon atoms which is substituted one or more times by halogen, oxo, or combinations thereof wherein optionally one or more —CH2CH2— groups are replaced in each case by —CH═CH— or —C≡C— groups,
cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl, or combinations thereof,
cycloalkylalkyl having 4 to 16 carbon atoms which is unsubstituted or substituted one or more times by halogen, oxo, alkyl or combinations thereof,
aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF3, OCF3, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido and acyloxy or combinations thereof,
arylalkyl having 8 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF3, OCF3, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido and acyloxy or combinations thereof,
a heterocyclic group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom which is unsubstituted or substituted one or more times by halogen, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof, or
a heterocyclic-alkyl group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, wherein the heterocyclic portion is unsubstituted or substituted one or more times by halogen, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, dialkylamino, carboxy or combinations thereof and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof; and
R5 is H,
alkyl having 1 to 12 carbon atoms wherein optionally one or more —CH2CH2— groups are replaced in each case by —CH═CH— or —C≡C— groups,
alkyl having 1 to 12 carbon atoms which is substituted one or more times by halogen, oxo, or combinations thereof wherein optionally one or more —CH2CH2— groups are replaced in each case by —CH═CH— or —C≡C— groups,
cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl, or combinations thereof,
cycloalkylalkyl having 4 to 16 carbon atoms which is unsubstituted or substituted one or more times by halogen, oxo, alkyl or combinations thereof,
aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF3, OCF3, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido and acyloxy or combinations thereof,
arylalkyl having 8 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF3, OCF3, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido and acyloxy, or combinations thereof,
a heterocyclic group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, which is unsubstituted or substituted one or more times by halogen, aryl, alkyl, alkoxy, alkoxycarbonyl, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof, or
a heterocyclic-alkyl group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, wherein the heterocyclic portion is unsubstituted or substituted one or more times by halogen, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, dialkylamino, carboxy or combinations thereof and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof;
and physiologically acceptable salts thereof,
wherein in each case the compound can be in the form of a mixture of enantiomers such as the racemate, or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer;
with the proviso that:
(a) when R2 is CH3 and R3 is H, then R1 is not methyl, ethyl, n-propyl, isopropyl, sec-butyl, n-butyl, isobutyl, neopentyl, n-pentyl, 2-methylbutyl, isopentyl, n-hexyl, phenyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl, methylcyclopentyl, cyclopropylmethyl, cyclopentylmethyl, 2-propenyl, 2-propynyl, 3-methyl-2-butenyl, N-substituted 2-piperazinylethyl, norbornyl, 3-tetrahydrofuryl, 2-tetrahydrofuryl, 3-tetrahydrothienyl, 2-oxacyclopropyl, 2-oxacyclopenyl, 3-oxacyclopentyl, 2-chloroethyl, 2-bromoethyl, 2,2,2-trifluoroethyl, 3-bromopropyl, 3-chloropropyl, or 4-bromobutyl;
(b) when R1 is cyclopentyl, and R2 is methyl, then R3 is not H, acetyl, benzyl, 4-hydroxybenzyl, 4-acetoxybenzyl, 4-bromobenzyl, 3,4-dimethoxybenzyl, 4-methylthiobenzyl, 4-cyanobenzyl, 2-aminobenzyl, 3-aminobenzyl, 4-aminobenzyl, 4-dimethylaminobenzyl, 2,4-diaminobenzyl, 4-amino-3,5-dimethoxybenzyl, 3-carboxybenzyl, 3-methoxycarbonylbenzyl, 4-methoxycarbonylbenzyl, 4-methylsulfinylbenzyl, 4-methylsulfonylbenzyl, 2-nitrobenzyl, 3-nitrobenzyl, 4-nitrobenzyl, 2,4-dinitrobenzyl, 2-nitro-4-aminobenzyl, 2-amino-4-nitrobenzyl, morpholinoethyl, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 4-(6-fluoroquinolyl)methyl, 2-(7-chloroquinolyl)methyl, 2-imidazoylmethyl, or substituted imidazoylmethyl;
(c) when R1 is CH3, and R3 is H, then R2 is not methyl, ethyl, or butyl;
(d) when R3 is H, then R1 and R2 are not both ethyl or isobutyl; and
(e) when R3 and R2 are both difluoromethyl, then R3 is not 4-aminobenzyl, or 4-amino-3,5-dimethoxybenzyl.
2-4. (canceled)
5. A compound of Formula I:
Figure US20090176799A1-20090709-C00011
wherein
X is O;
R1 is alkyl having 1 to 8 carbon atoms wherein optionally one or more —CH2CH2— groups are replaced in each case by —CH═CH— or —C≡C— groups,
alkyl having 1 to 8 carbon atoms which is substituted one or more times by halogen, oxo or combinations thereof wherein optionally one or more —CH2CH2— groups are replaced in each case by —CH═CH— or —C≡C— groups,
cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl having 1 to 4 carbon atoms or combinations thereof,
a heterocyclic group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, which is unsubstituted or substituted one or more times by halogen, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof,
aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF3 OCF3, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido and acyloxy, or combinations thereof,
arylalkyl having 8 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF3 OCF3, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido and acyloxy, or combinations thereof,
a partially unsaturated carbocyclic group having 5 to 14 carbon atoms which is unsubstituted or substituted one or more times by halogen, alkyl, alkoxy, nitro, cyano, oxo, or combinations thereof,
arylalkenyl having 8 to 16 carbon atoms, wherein the alkenyl portion has up to 5 carbon atoms, which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido and acyloxy or combinations thereof;
a heterocyclic-alkyl group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, wherein the heterocyclic portion is unsubstituted or substituted one or more times by halogen, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, dialkylamino, carboxy or combinations thereof and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof, or
cycloalkylalkyl having 4 to 16 carbon atoms which is unsubstituted or substituted one or more times by halogen, oxo, alkyl or combinations thereof,
R2 is CHF2;
R3 is H,
arylalkyl having 7 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, and acyloxy or combinations thereof,
a heterocyclic-alkyl group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, wherein the heterocyclic portion is unsubstituted or substituted one or more times by halogen, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, dialkylamino, carboxy or combinations thereof and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof,
alkoxyalkyl having 3 to 8 carbon atoms,
—C(O)R4, or
—CH2CONHR5;
R4 is aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF3, OCF3, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido and acyloxy or combinations thereof, or
a heterocyclic group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, which is unsubstituted or substituted one or more times by halogen, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof; and
R5 is aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF3, OCF3, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido and acyloxy or combinations thereof, or
a heterocyclic group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, which is unsubstituted or substituted one or more times by halogen, aryl, alkyl, alkoxy, alkoxycarbonyl, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof;
and physiologically acceptable salts thereof,
wherein in each case the compound can be in the form of a mixture of enantiomers such as the racemate, or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer;
with the proviso that:
(a) when R1 and R2 are both difluoromethyl, then R3 is not 4-aminobenzyl, or 4-amino-3,5-dimethoxybenzyl.
6. A compound according to claim 1, wherein R1 is optionally substituted cycloalkyl, cycloalkylalkyl, aryl, a heterocyclic group, arylalkyl, or a partially unsaturated carbocyclic group, or is CHF2.
7. A compound according to claim 6, wherein R1 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentylethyl, cyclopropylmethyl, phenyl, napthyl, phenethyl, phenpropyl, furanyl, pyrazinyl, pyrimidinyl, pyridyl, quinolinyl, isoquinolinyl, thienyl, indanyl, tetrahydrofuranyl, phenylpropenyl, phenyl substituted by one or more substituents selected from oxo, F, Cl, CF3, alkyl, alkoxy, CN, vinyl, methylenedioxy, COOH, and combinations thereof, or phenethyl substituted by one or more substituents selected from oxo, F, Cl, CF3, alkyl, alkoxy, CN, vinyl, methylenedioxy, COOH, and combinations thereof.
8. A compound according to claim 1, wherein when R3 is other than H, R1 is CHF2, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl or a heterocyclic group.
9. A compound according to claim 1, wherein when R3 is other than H, R1 is CHF2 or is optionally substituted cyclopentyl, phenethyl, 3-tetrahydrofuranyl, or cyclopropylmethyl.
10. A compound according to claim 1, wherein R2 is substituted or unsubstituted alkyl having 1 to 4 carbon atoms.
11. A compound according to claim 10, wherein R2 is CHF2 or CH3.
12. A compound according to claim 1, wherein R3 is H, substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl, CH2CONHR5 or COR4.
13. A compound according to claim 12, wherein R3 is H, substituted benzyl or CH2CONHR5.
14. A compound according to claim 12, wherein R3 is methyl, ethyl, propyl, n-butyl, methylbenzyl, fluorobenzyl, difluorobenzyl, chlorobenzyl, methoxy, benzyl, cyanobenzyl, dichlorobenzyl, chlorofluorobenzyl, trifluoromethylbenzyl, or bis(trifluoromethyl)benzyl.
15. A compound according to claim 1, wherein R3 is COR4 and R4 is an optionally substituted aryl or heterocyclic group.
16. A compound according to claim 15, wherein R4 is phenyl or phenyl substituted by one or more substituents selected from F, Cl, CH3, C2H5, OCH3, COOH, CN and combinations thereof.
17. (canceled)
18. (canceled)
19. A compound according to claim 6, wherein R2 is CH3 or CHF2.
20. A compound according to claim 1, wherein R2 is CH3 or CHF2, R1 is CHF2, cyclopentyl, tetrahydrofuran, phenethyl or cyclopropylmethyl, and R3 is not H.
21-30. (canceled)
31. A compound according to claim 1, wherein the compound of formula I is selected from:
4-[4-Methoxy-3-(4-methoxyphenoxy)phenyl]-2-pyrrolidone,
4-[4-Methoxy-3-(3-thienyloxy)phenyl]-2-pyrrolidone,
4-[3-(4-Fluorophenoxy)-4-methoxyphenyl]-2-pyrrolidone,
4-(3-(3-Cyclohexyl-1-propyloxy)-4-methoxyphenyl)-2-pyrrolidone,
4-(4-Methoxy-3-(2-phenylethoxy)phenyl)-2-pyrrolidone,
4-(4-Methoxy-3-(3-phenyl-1-propoxy)phenyl)-2-pyrrolidone,
4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-chloro-4-fluorobenzyl)-2-pyrrolidone,
Methyl 4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone-1-acetate,
4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-cyanomethyl-2-pyrrolidone,
4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-cyclopentyl-2-pyrrolidone,
4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(4-methoxybenzoyl)-2-pyrrolidone,
4(S)-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-1-(N-(2-(6-methylpyridyl))-aminocarbonylmethyl)-2-pyrrolidone,
1-(N-(2,3-Difluorophenyl)-aminocarbonylmethyl)-4(S)-(4-methoxy-3-(3(R)-tetrahydrofuryloxy)phenyl)-2-pyrrolidone,
4(S)-(4-Methoxy-3-(3(R)-tetrahydrofuryloxy)phenyl)-1-(N-(2-methylphenyl)-aminocarbonylmethyl)-2-pyrrolidone,
4(S)-(4-Methoxy-3-(3(R)-tetrahydrofuryloxy)phenyl)-1-(N-(2-(6-methylpyridinyl))-aminocarbonylmethyl)-2-pyrrolidone, and
physiologically acceptable salts thereof, wherein in each case the compound can be in the form of a mixture of enantiomers such as the racemate, or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.
32. A compound according to claim 1, wherein the compound of formula I is selected from:
(4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-methylbenzyl)-2-pyrrolidone,
(4S)-1-(2-Chlorobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
(4S)-1-(4-Chlorobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
(4S)-1-(3-Chlorobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
(4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3-methoxybenzyl)-2-pyrrolidone,
(4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-fluorobenzyl)-2-pyrrolidone,
(4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3-fluorobenzyl)-2-pyrrolidone,
(4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(4-fluorobenzyl)-2-pyrrolidone,
(4S)-1-(4-Cyanobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
(4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-trifluoromethylbenzyl)-2-pyrrolidone,
(4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3-trifluoromethylbenzyl)-2-pyrrolidone,
(4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(4-trifluoromethylbenzyl)-2-pyrrolidone,
(4S)-1-(3,5-bistrifluoromethylbenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
(4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3,4-difluorobenzyl)-2-pyrrolidone,
(4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3,5-difluorobenzyl)-2-pyrrolidone,
(4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2,4-difluorobenzyl)-2-pyrrolidone,
(4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2,6-difluorobenzyl)-2-pyrrolidone,
(4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2,3-difluorobenzyl)-2-pyrrolidone,
(4S)-1-(2-Chloro-4-fluorobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
(4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3,4-dichlorobenzyl)-2-pyrrolidone,
(4S)-1-(4-tert-Butylbenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
(4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-ethyl-2-pyrrolidone,
(4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-propyl-2-pyrrolidone,
(4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-butyl-2-pyrrolidone,
(4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-methoxyethyl)-2-pyrrolidone,
(4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-phenylbenzyl)-2-pyrrolidone,
(4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-methylbenzyl)-2-pyrrolidone,
(4R)-1-(2-Chlorobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
(4R)-1-(4-Chlorobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
(4R)-1-(3-Chlorobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
(4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3-methoxybenzyl)-2-pyrrolidone,
(4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-fluorobenzyl)-2-pyrrolidone,
(4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3-fluorobenzyl)-2-pyrrolidone,
(4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(4-fluorobenzyl)-2-pyrrolidone,
(4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-trifluoromethylbenzyl)-2-pyrrolidone,
(4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3-trifluoromethylbenzyl)-2-pyrrolidone,
(4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(4-trifluoromethylbenzyl)-2-pyrrolidone,
(4R)-1-(3,5-bistrifluoromethylbenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
(4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3,4-difluorobenzyl)-2-pyrrolidone,
(4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3,5-difluorobenzyl)-2-pyrrolidone,
(4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2,4-difluorobenzyl)-2-pyrrolidone,
(4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2,6-difluorobenzyl)-2-pyrrolidone,
(4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2,3-difluorobenzyl)-2-pyrrolidone,
(4R)-1-(2-Chloro-4-fluorobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
(4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(3,4-dichlorobenzyl)-2-pyrrolidone,
(4R)-1-(4-tert-Butylbenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
(4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-ethyl-2-pyrrolidone,
(4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-propyl-2-pyrrolidone,
(4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-butyl-2-pyrrolidone,
(4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-methoxyethyl)-2-pyrrolidone,
(4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(2-phenylbenzyl)-2-pyrrolidone,
(4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2,6-dimethylphenyl)-aminocarbonylmethyl)-2-pyrrolidone,
(4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2,6-dimethylphenyl)-aminocarbonylmethyl)-2-pyrrolidone,
4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2-methylphenyl)-aminocarbonylmethyl)-2-pyrrolidone,
(4R)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2-methylphenyl)-aminocarbonylmethyl)-2-pyrrolidone,
(4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2-methylphenyl)-aminocarbonylmethyl)-2-pyrrolidone,
4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2,3-difluorophenyl)-aminocarbonylmethyl)-2-pyrrolidone,
4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(3-chlorophenyl)-aminocarbonylmethyl)-2-pyrrolidone,
4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(4-pyridyl)-aminocarbonylmethyl)-2-pyrrolidone,
4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(4-methoxyphenyl)-aminocarbonylmethyl)-2-pyrrolidone,
4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(4-chloro-2-fluorophenyl)-aminocarbonylmethyl)-2-pyrrolidone,
4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(3-methylphenyl)-aminocarbonylmethyl)-2-pyrrolidone,
4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(4-methylphenyl)-aminocarbonylmethyl)-2-pyrrolidone,
4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(4-nitrophenyl)-aminocarbonylmethyl)-2-pyrrolidone,
4-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-1-(N-(2,3-difluorophenyl)-aminocarbonylmethyl)-2-pyrrolidone,
4(S)-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-1-(N-(2-(6-methylpyridyl))-aminocarbonylmethyl)-2-pyrrolidone,
4(S)-(4-Methoxy-3-(3(R)-tetrahydrofuryloxy)phenyl)-1-(N-(2-(6-methylpyridyl))-aminocarbonylmethyl)-2-pyrrolidone,
1-(N-(2,3-Difluorophenyl)-aminocarbonylmethyl)-4(S)-(4-methoxy-3-(3(R)-tetrahydrofuryloxy)phenyl)-2-pyrrolidone,
1-(N-(2-(6-Aminopyridyl))-aminocarbonylmethyl)-4(S)-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
4(S)-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2-(6-ethylpyridyl))-aminocarbonylmethyl)-2-pyrrolidone,
4(S)-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2-(4,6-dimethylpyridyl))-aminocarbonylmethyl)-2-pyrrolidone,
1-(N-(2-(6-Bromopyridyl))-aminocarbonylmethyl)-4(S)-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
1-(N-(2-(6-Bromopyridyl))-aminocarbonylmethyl)-4(S)-(4-methoxy-3-(3(R)-tetrahydrofuryloxy)phenyl)-2-pyrrolidone,
4(S)-(4-Methoxy-3-(3(R)-tetrahydrofuryloxy)phenyl)-1-(N-(2-methylphenyl)-aminocarbonylmethyl)-2-pyrrolidone,
4(S)-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(3-(2-methoxypyridyl))-aminocarbonylmethyl)-2-pyrrolidone,
1-(N-(6-(3-Bromo-2-methylpyridyl))-aminocarbonylmethyl)-4(S)-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone,
4(S)-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(3-(4-methoxycarbonyl)-pyridyl)-aminocarbonylmethyl)-2-pyrrolidone,
4(S)-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(N-(2-(6-methylpyridyl))-aminocarbonylmethyl)-2-pyrrolidone,
1-(N-(3-(2-Cyanopyridyl))-aminocarbonylmethyl)-4(S)-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone, or
4(S)-(4-Methoxy-3-(3(R)-tetrahydrofuryloxy)phenyl)-1-(N-(2-(6-methylpyridinyl))-aminocarbonylmethyl)-2-pyrrolidone, and
physiologically acceptable salts thereof, wherein in each case the compound can be in the form of a mixture of enantiomers such as the racemate, or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.
33-61. (canceled)
US12/325,433 2001-10-16 2008-12-01 Phosphodiesterase 4 inhibitors Abandoned US20090176799A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/325,433 US20090176799A1 (en) 2001-10-16 2008-12-01 Phosphodiesterase 4 inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32931401P 2001-10-16 2001-10-16
US10/270,724 US7235579B2 (en) 2001-10-16 2002-10-16 Phosphodiesterase 4 inhibitors
US11/186,958 US20050272803A1 (en) 2001-10-16 2005-07-22 Phosphodiesterase 4 inhibitors
US12/325,433 US20090176799A1 (en) 2001-10-16 2008-12-01 Phosphodiesterase 4 inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/186,958 Continuation US20050272803A1 (en) 2001-10-16 2005-07-22 Phosphodiesterase 4 inhibitors

Publications (1)

Publication Number Publication Date
US20090176799A1 true US20090176799A1 (en) 2009-07-09

Family

ID=23284824

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/270,724 Expired - Fee Related US7235579B2 (en) 2001-10-16 2002-10-16 Phosphodiesterase 4 inhibitors
US11/186,958 Abandoned US20050272803A1 (en) 2001-10-16 2005-07-22 Phosphodiesterase 4 inhibitors
US12/325,433 Abandoned US20090176799A1 (en) 2001-10-16 2008-12-01 Phosphodiesterase 4 inhibitors

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US10/270,724 Expired - Fee Related US7235579B2 (en) 2001-10-16 2002-10-16 Phosphodiesterase 4 inhibitors
US11/186,958 Abandoned US20050272803A1 (en) 2001-10-16 2005-07-22 Phosphodiesterase 4 inhibitors

Country Status (20)

Country Link
US (3) US7235579B2 (en)
EP (1) EP1435944B1 (en)
JP (2) JP4484515B2 (en)
KR (2) KR20090080573A (en)
CN (1) CN1604776A (en)
AT (1) ATE444065T1 (en)
AU (1) AU2002335015B8 (en)
BR (1) BR0213660A (en)
CA (1) CA2463469A1 (en)
CO (1) CO5570674A2 (en)
DE (1) DE60233884D1 (en)
ES (1) ES2334650T3 (en)
HR (1) HRP20040409A2 (en)
IL (1) IL161317A0 (en)
MX (1) MXPA04003516A (en)
NO (1) NO20042024L (en)
NZ (1) NZ532288A (en)
RU (2) RU2340600C2 (en)
WO (1) WO2003032981A1 (en)
ZA (1) ZA200402856B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637559B2 (en) 2005-11-15 2014-01-28 Otsuka Pharmaceutical Co., Ltd. Oxazole compound and pharmaceutical composition

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8153646B2 (en) 2000-08-10 2012-04-10 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US9931318B2 (en) 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
AU2002248180A1 (en) * 2000-12-14 2002-07-16 The Burnham Institute Non-apoptotic forms of cell death and methods of modulation
ATE444065T1 (en) 2001-10-16 2009-10-15 Memory Pharm Corp 4(4-ALKOXY-3-HYDROXYPHENYL)-2-PYRROLIDONE DERIVATIVES AS PDE-4 INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL SYNDROMES
US20030157053A1 (en) * 2002-02-19 2003-08-21 Sabina Sperandio Modulators of paraptosis and related methods
US7495016B2 (en) 2002-10-21 2009-02-24 Irm Llc Pyrrolidones with anti-HIV activity
ES2211344B1 (en) * 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA.
AU2004232958A1 (en) * 2003-04-16 2004-11-04 F.-Hoffmann La-Roche Inc. 4 - (3,4 - disubstituted phenyl) - pyrrolidin-2-one compounds as phosphodiesterase 4 inhibitors
EP1624873A2 (en) * 2003-04-28 2006-02-15 AB Science Use of tyrosine kinase inhibitors for treating cerebral ischemia
ES2251866B1 (en) * 2004-06-18 2007-06-16 Laboratorios Almirall S.A. NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA.
ES2251867B1 (en) * 2004-06-21 2007-06-16 Laboratorios Almirall S.A. NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA.
DOP2005000123A (en) * 2004-07-02 2011-07-15 Merck Sharp & Dohme CETP INHIBITORS
US7585882B2 (en) 2004-10-20 2009-09-08 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
RU2513107C2 (en) * 2005-12-30 2014-04-20 Мерк Шарп И Доум Корп. Cetp inhibitors
SG10201407258RA (en) * 2006-05-19 2015-01-29 Dart Neuroscience Cayman Ltd Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
ES2320954B1 (en) * 2007-03-02 2010-03-16 Laboratorio Almirall S.A. NEW PREPARATION PROCEDURE FOR 3-METHYL-4-PHENYLISOXAZOLO (3,4-D) IRIDAZIN-7 (6H) -ONA.
WO2009067607A2 (en) * 2007-11-20 2009-05-28 Memory Pharmaceuticals Corporation Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders
CN107243007A (en) 2008-10-16 2017-10-13 约翰斯.霍普金斯大学 Improve the method and composition of cognitive function
WO2010075086A2 (en) * 2008-12-15 2010-07-01 Auspex Pharmaceuticals, Inc. Pyrrolidinone inhibitors of pde-4
EP2443089B1 (en) 2009-06-18 2014-03-05 Concert Pharmaceuticals Inc. Deuterated isoindoline-1,3-dione derivatives as pde4 and tnf-alpha inhibitors
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
CA2900302C (en) 2013-02-19 2018-07-03 Pfizer Inc. Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders
HK1218623A1 (en) 2013-03-15 2017-03-03 艾吉因生物股份有限公司 Methods and compositions for improving cognitive function
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
JP6713982B2 (en) 2014-07-24 2020-06-24 ファイザー・インク Pyrazolopyrimidine compounds
HUE044040T2 (en) 2014-08-06 2019-09-30 Pfizer Imidazopyridazine compounds
MX384391B (en) 2015-05-22 2025-03-14 Agenebio Inc Extended release pharmaceutical compositions of levetiracetam
TWI877358B (en) * 2020-04-29 2025-03-21 大陸商廣東東陽光藥業股份有限公司 Substituted pyrrolidine compounds and their applications in medicine
CN112479966B (en) * 2020-12-11 2022-05-17 南京工业大学 Method for synthesizing rolipram

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4012495A (en) * 1974-03-20 1977-03-15 Schering Aktiengesellschaft 4-(Polyalkoxyphenyl)-2-pyrrolidones
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
US4219551A (en) * 1978-08-01 1980-08-26 Schering Aktiengesellschaft Aminoalkoxyphenylpyrrolidone antihypertonic agents and use thereof
US5128358A (en) * 1988-01-19 1992-07-07 Pfizer Inc. Aryl substituted nitrogen heterocyclic antidepressants
US5539111A (en) * 1989-06-28 1996-07-23 Schering Aktiengesellschaft Process for resolution of racemates of 4-aryl-2-oxo-pyrrolidine-3-carboxylic acid esters
US5814651A (en) * 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
US5846514A (en) * 1994-03-25 1998-12-08 Isotechnika, Inc. Enhancement of the efficacy of nifedipine by deuteration
US5935978A (en) * 1991-01-28 1999-08-10 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
US6136821A (en) * 1996-10-28 2000-10-24 Novartis Ag Naphthyridine derivatives
US6258833B1 (en) * 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6334997B1 (en) * 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6372777B1 (en) * 1999-12-23 2002-04-16 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6495154B1 (en) * 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3438839A1 (en) * 1984-10-19 1986-04-24 Schering AG, 1000 Berlin und 4709 Bergkamen PHARMACEUTICAL PREPARATIONS
GB9009395D0 (en) 1990-04-26 1990-06-20 Orion Yhtymae Oy Cyclic hydroxamic acids and their use
PT100441A (en) 1991-05-02 1993-09-30 Smithkline Beecham Corp PIRROLIDINONES, ITS PREPARATION PROCESS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE
WO1993007141A1 (en) 1991-10-11 1993-04-15 Smithkline Beecham Corporation Heterocyclic 3-phenylpyrrolidin-2-ones, their preparation and use for the manufacture of a medicament for inhibiting tumor necrosis factor production
AU670949B2 (en) 1992-06-15 1996-08-08 Celltech Limited Trisubstituted phenyl derivatives as selective phosphodiesterase IV inhibitors
KR950704228A (en) * 1992-12-02 1995-11-17 알렌 제이. 스피겔 CATECOL DIETHERS AS SELECTIVE PDE_IV INHIBITORS as Selective Phosphodiester Hydrolase Type IV (PDE_IV) Inhibitors
TW263495B (en) 1992-12-23 1995-11-21 Celltech Ltd
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
JPH07300455A (en) * 1994-03-08 1995-11-14 Mitsubishi Chem Corp 3-phenylpyrrolidine derivative
PT758233E (en) 1994-04-21 2004-04-30 Schering Ag PDE IV INHIBITORS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
GB9412383D0 (en) 1994-06-21 1994-08-10 Celltech Ltd Chemical compound
DE19601938A1 (en) 1996-01-12 1997-07-17 Schering Ag New phosphodiesterase inhibitors
JPH1072415A (en) 1996-06-26 1998-03-17 Nikken Chem Co Ltd 3-anilino-2-cycloalkenone derivatives
US6235736B1 (en) 1997-06-24 2001-05-22 Nikken Chemicals Co., Ltd. 3-anilino-2-cycloalkenone derivatives
JP3085249B2 (en) 1997-07-09 2000-09-04 松下電器産業株式会社 Hot plate
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
CA2402384A1 (en) 2000-03-16 2001-09-20 Inflazyme Pharmaceuticals Ltd. Benzylated pde4 inhibitors
AU2002241596A1 (en) 2000-11-02 2002-06-18 Research Foundation Of City University Of New York Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4
ATE444065T1 (en) 2001-10-16 2009-10-15 Memory Pharm Corp 4(4-ALKOXY-3-HYDROXYPHENYL)-2-PYRROLIDONE DERIVATIVES AS PDE-4 INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL SYNDROMES
AU2004232958A1 (en) 2003-04-16 2004-11-04 F.-Hoffmann La-Roche Inc. 4 - (3,4 - disubstituted phenyl) - pyrrolidin-2-one compounds as phosphodiesterase 4 inhibitors

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
US4012495A (en) * 1974-03-20 1977-03-15 Schering Aktiengesellschaft 4-(Polyalkoxyphenyl)-2-pyrrolidones
US4219551A (en) * 1978-08-01 1980-08-26 Schering Aktiengesellschaft Aminoalkoxyphenylpyrrolidone antihypertonic agents and use thereof
US5128358A (en) * 1988-01-19 1992-07-07 Pfizer Inc. Aryl substituted nitrogen heterocyclic antidepressants
US5539111A (en) * 1989-06-28 1996-07-23 Schering Aktiengesellschaft Process for resolution of racemates of 4-aryl-2-oxo-pyrrolidine-3-carboxylic acid esters
US5935978A (en) * 1991-01-28 1999-08-10 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
US5814651A (en) * 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
US5846514A (en) * 1994-03-25 1998-12-08 Isotechnika, Inc. Enhancement of the efficacy of nifedipine by deuteration
US6334997B1 (en) * 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6136821A (en) * 1996-10-28 2000-10-24 Novartis Ag Naphthyridine derivatives
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6258833B1 (en) * 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6372777B1 (en) * 1999-12-23 2002-04-16 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6423710B1 (en) * 1999-12-23 2002-07-23 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6495154B1 (en) * 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637559B2 (en) 2005-11-15 2014-01-28 Otsuka Pharmaceutical Co., Ltd. Oxazole compound and pharmaceutical composition
USRE46792E1 (en) 2005-11-15 2018-04-17 Otsuka Pharmaceutical Co., Ltd. Oxazole compound and pharmaceutical composition

Also Published As

Publication number Publication date
NZ532288A (en) 2005-12-23
RU2004115333A (en) 2005-10-27
JP2009286797A (en) 2009-12-10
US20050272803A1 (en) 2005-12-08
CO5570674A2 (en) 2005-10-31
EP1435944B1 (en) 2009-09-30
WO2003032981A1 (en) 2003-04-24
RU2008123376A (en) 2009-12-27
IL161317A0 (en) 2004-09-27
KR20090080573A (en) 2009-07-24
HRP20040409A2 (en) 2005-06-30
BR0213660A (en) 2004-08-24
DE60233884D1 (en) 2009-11-12
AU2002335015B2 (en) 2006-11-02
NO20042024L (en) 2004-05-14
MXPA04003516A (en) 2004-07-23
ATE444065T1 (en) 2009-10-15
US7235579B2 (en) 2007-06-26
KR100951218B1 (en) 2010-04-05
JP4484515B2 (en) 2010-06-16
CA2463469A1 (en) 2003-04-24
JP2005508961A (en) 2005-04-07
EP1435944A1 (en) 2004-07-14
KR20050037404A (en) 2005-04-21
CN1604776A (en) 2005-04-06
ES2334650T3 (en) 2010-03-15
AU2002335015B8 (en) 2006-11-30
ZA200402856B (en) 2005-01-25
US20030139406A1 (en) 2003-07-24
RU2340600C2 (en) 2008-12-10

Similar Documents

Publication Publication Date Title
US7235579B2 (en) Phosphodiesterase 4 inhibitors
US7696198B2 (en) Phosphodiesterase 4 inhibitors
AU2002335015A1 (en) 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes
US7700631B2 (en) Phosphodiesterase 4 inhibitors
EP1692109B1 (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
US20100010020A1 (en) Phosphodiesterase 4 inhibitors
US7655802B2 (en) Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US7153871B2 (en) Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US7585882B2 (en) Phosphodiesterase 4 inhibitors
MXPA05011055A (en) 4 - (3,4 - disubstituted phenyl) - pyrrolidin-2-one compounds as phosphodiesterase 4 inhibitors
HK1114617A (en) Phosphodiesterase 4 inhibitors
NZ547469A (en) 6-Amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION